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Abstract 
Campylobacter jejuni and C. coli are  among  the  most  important  bacterial  enteropathogens  
worldwide, and the last decade Campylobacter infections in the European Union (EU) have 
shown a rising trend in incidence. The most commonly reported zoonosis in the EU, 
campylobacteriosis, can be transmitted to humans from a wide variety of wild birds, as well 
as from domestic and pet animals. Eating or handling raw or undercooked meat, particularly 
poultry, is considered the primary risk factor for Campylobacter infection, followed by other 
risk factors such as drinking unpasteurized milk or contaminated water, contact with 
domestic pets, and swimming in natural water sources. 
 
The enteric disease caused by C. jejuni or C. coli is characterized by profuse watery diarrhea, 
fever, abdominal pain, nausea, and sometimes bloody stools. The disease usually lasts from a 
few days up to one week, and although Campylobacter infection usually resolves 
spontaneously without antimicrobial treatment, prolonged symptomatic periods and relapses 
do occur. 
 
A complication that commonly follows and is attributed to Campylobacter infection is 
reactive arthritis, which occurs in approximately 1 to 10% of the patients. Closely associated 
with C. jejuni infection is also the more rarely encountered serious inflammatory 
polyneuropathy Guillain-Barré syndrome. Bacteremia due to C. jejuni or C. coli has been 
estimated to develop in 0.1 to 1% of patients with campylobacteriosis, and hematogenously 
spread disease is considered more common in older patients and those with severe underlying 
diseases. 
 
The bacterial characteristics of C. jejuni or C. coli which could lead to a more severe course 
of disease, to bacteremia, or to post-infectious complications are not well understood. Certain 
putative virulence factors have been suggested to be of importance for either the invasiveness 
or the colonization potential of C. jejuni,  some  examples  of  which  are  the  plasmid  pVir,  
Campylobacter invasion antigen, and ?-glutamyl transpeptidase (GGT). Other examples of 
putative virulence factors include those suspected to affect the bacterium’s iron uptake, 
survival or metabolism. Moreover, because of the seriousness of Guillain-Barré syndrome, 
development of post-infectious adverse immune responses has been subject to specific focus, 
and structural differences in the lipooligosaccharide in the outer membrane of C. jejuni have 
been under extensive study. The relevance of these bacterial factors to the actual clinical 
disease outcome has yet to be explained, however, possibly with the exception of the 
relatively clear association between sialylated lipooligosaccharides and the development of 
the Guillain-Barré syndrome. The primary goal of this PhD study was therefore to try to 
define which bacterial factors could lead to a more severe outcome of Campylobacter 
infection. 
 
Two sets of patient data, along with the corresponding bacterial isolates of those patients, 
were included. The first was questionnaire-based, and collected from the Uusimaa region in 
southern Finland during July through December, 2006. The 192 patients included had been 
diagnosed as stool culture-positive for C. jejuni or C. coli, and all returned their 
questionnaires along with their informed consent. The second set of data was retrospective, 
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nationwide, and register-based, and included 76 patients diagnosed with C. jejuni or C. coli 
bacteremia during a 10-year period in Finland, 1998-2007. 
 
The isolates from patients with enteritis were tested for antimicrobial susceptibility, the 
presence of putative virulence factor genes, and the production of GGT. Multilocus sequence 
typing (MLST) as well as determination of susceptibility to normal human serum was 
performed on the isolates from the patients with bacteremia. All C. jejuni isolates were tested 
for production of GGT, and in addition, the presence of the following putative virulence 
factor genes was tested by polymerase chain reaction (PCR) for all isolates; ceuE, ciaB, 
cj0486, and virB11, and additionally the gene cluster cdtABC and the genes cgtB, pldA, and 
wlaN for the enteritis isolates. For the bacteremia isolates, PCR analyses allowed 
determination of the MLST profiles and lipooligosaccharide (LOS) locus classes of the 
isolates. 
 
Results of multivariate analyses revealed bacterial differences based on the origin of infection 
among the enteritis isolates, as domestically acquired infections were significantly associated 
with the production of GGT, while imported infections were significantly associated with 
ceuE and cj0486. 
 
Susceptibilities of the bacterial isolates were tested for those antimicrobial agents most 
commonly  used  in  the  treatment  of  Campylobacter infections, and when these data were 
compared with the clinical information, some interesting findings emerged. First, among the 
patients  with  enteritis,  bacterial  resistance  to  ciprofloxacin  did  not  seem  to  lead  to  more  
severe disease outcome. Instead, this was specifically attributed more to those isolates highly 
susceptible to ciprofloxacin. Second, the majority of the bacteremia isolates were susceptible 
to all tested antimicrobial agents. Third, among the patients with bacteremia, appropriate and 
empirical antimicrobial treatment affected neither patients’ duration of hospitalization nor the 
mortality attributable to the infection, to any greater extent. 
 
The C. jejuni and C. coli bacteremia patients were moderately young (median age, 46 years) 
and according to the Charlson weighted index of comorbidity, underlying diseases regarded 
as comorbidities significantly affecting disease outcome affected only 30%. 
 
Among the bacteremia isolates, MLST revealed the clonal complexes ST-677, ST-45, and 
ST-21 to be the most prevalent, accounting for 48%, 16%, and 14%, of the isolates. All the 
isolates of the ST-677 complex originated from patients diagnosed with C. jejuni bacteremia 
during the seasonal peak in May through August; these isolates were significantly more 
serum resistant than were all other isolates, and all isolates of the ST-677 complex had 
nonsialylated LOS. Isolates of the ST-45 complex were associated with production of GGT 
and were significantly more serum sensitive than were all other isolates, and all the ST-45 
complex isolates had nonsialylated LOS. Isolates of the ST-21 complex were associated with 
the gene cj0486, and all these isolates had sialylated LOS. 
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1. Introduction 
In  most  parts  of  the  world Campylobacter infection is common, with campylobacteriosis 
being the most frequently reported zoonosis in the European Union, as well as the most 
prevalent cause of bacterial enteritis in Europeans (EFSA, 2005; EFSA, 2009). Raw or 
undercooked meat, especially poultry, is considered the primary source of infection (Harris et 
al., 1986; Neal & Slack, 1995; Studahl & Andersson, 2000). In addition, contaminated 
drinking water (Schönberg-Norio et al., 2004), domestic pet contact (Kapperud et al., 1992; 
Friedman et al., 2004), and even swimming in natural sources of water (Schönberg-Norio et 
al., 2004) are important risk factors for Campylobacter infection. 
 
The typical symptoms of Campylobacter enteritis include diarrhea, fever, abdominal cramps 
and pain, which sometimes may become so intense that it even mimics the pain during acute 
appendicitis (Blaser, 1997). Blood and mucus in the stools are also quite common, and some 
patients experience myalgia or nausea and sometimes, vomiting (Butzler & Skirrow, 1979). 
Bloody stools and vomiting have been regarded as more severe symptoms of Campylobacter 
infection (Gillespie et al., 2006). 
 
Of the species of Campylobacter, C. jejuni, C. coli and C. fetus are of special clinical interest. 
C. jejuni is the most commonly isolated bacterial enteropathogen from stool samples of 
patients with diarrhea, and C. coli is the second most prevalent Campylobacter spp. isolated 
from enteritis patients. C. fetus is  usually  not  isolated  from  fecal  samples,  but  it  causes  
extraintestinal infections, particularly in immunocompromised hosts, and it is sometimes 
isolated from blood (Lastovica & Allos, 2008). 
 
Campylobacter bacteremia is uncommon, as it occurs in only approximately 0.1 to 1% of 
patients with Campylobacter enteritis  (Skirrow et  al.,  1993;  Samuel  et  al.,  2004;  Nielsen  et  
al., 2010a), and is usually neither a septic nor a life-threatening condition in patients without 
significant underlying diseases (Pigrau et al., 1997; Tee & Mijch, 1998). Mortality 
attributable to the bacteremic episode has ranged from 4 to 16% in previous studies (Reed et 
al., 1996; Pigrau et al., 1997; Tee & Mijch, 1998; Pacanowski et al., 2008; Fernández-Cruz et 
al., 2010; Nielsen et al., 2010a). The distribution of C. jejuni, C. fetus and C. coli in 
bacteremia differs to some extent among studies, and the exact distribution of these species is 
unknown, as identification of the isolates by molecular methods is usually lacking. 
 
Bacterial factors affecting the severity and outcome of Campylobacter infection are not well 
recognized. Some putative virulence factors may be of importance, including the cytolethal 
distending  toxin  (CDT)  which  causes  cell  cycle  arrest  (Lara-Tejero  &  Galán,  2001),  ?-
glutamyl transpeptidase (GGT), which plays a role in colonization in animal models 
(Hofreuter et al., 2006; Barnes et al., 2007), lipooligosaccharide (LOS), certain factors of 
which may enhance bacterial fitness (Habib et al., 2009), the fucose permease cj0486 
(Fearnley et al., 2008; Stahl et al., 2011), and the disputed plasmid pVir (Tracz et al., 2005; 
Louwen et al., 2006) which may affect the invasive capability of C. jejuni. 
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Treatment of Campylobacter infection with antimicrobial agents is common in many 
countries, although the overall effect of antimicrobial treatment seems limited (Ternhag et al., 
2007). 
 
In order to better understand which bacterial factors could be of importance for the outcome 
of Campylobacter infection or the severity of symptoms in the human host, it is important to 
combine well-defined clinical materials with analyses of the characteristics of the bacterial 
isolates.  The  aim  of  this  PhD  thesis  was  to  study  whether  any  specific  factors  exist  which  
may lead to more severe Campylobacter infections.  
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2. Review of the literature 
2.1 Historical aspects 
Although the appropriate taxonomy of Campylobacter was introduced in the 1970’s, bacteria 
belonging to this genus were actually first described by Theodor Escherich in 1886, a fact 
elegantly pointed out by Butzler along with a summary of some other important historical 
perspectives regarding the recognition of Campylobacter as a significant human pathogen 
(Butzler, 2004). In short, the genus name Vibrio was first suggested by Smith and Taylor in 
the beginning of the 20th century for these spirillum-like bacteria. In addition to the type 
species, Vibrio fetus, other catalase-positive “related vibrios” (King, 1957) were recognized 
as human pathogens in the 1950’s. The cornerstones for recognizing the clinical importance 
of these “vibrios”, the term used for Campylobacter through the first half of the 20th century, 
were the isolation of “Vibrio fetus” from the blood of a pregnant woman with fever (Vinzent 
et al., 1947), the isolation of a “related vibrio” from human feces (Dekayser et al., 1972), and 
the development of a selective culture medium in order to simplify the isolation of 
Campylobacter from feces (Skirrow, 1977). These three important scientific achievements 
revealed that Campylobacter is a pathogenic genus which can be detected and isolated from 
both the blood and fecal samples of humans with a range of different clinical symptoms. 
After introduction of the term Campylobacter, Greek for ‘curved rod’ (Sebald & Véron, 
1963; Véron & Chatelain, 1973), and once the technique needed for isolation from fecal 
samples was known (Skirrow, 1977), Campylobacter enteritis was recognized and described 
as an important human disease (Butzler & Skirrow, 1979; Blaser & Reller 1981). 
 
Campylobacter has since been generally accepted as a clinically relevant zoonosis and an 
important human enteropathogen, with an incidence of campylobacteriosis estimated as 
higher than that of many other bacterial pathogens which cause febrile gastroenteritis.
  
2.2 Bacteriology 
2.2.1 General description 
Campylobacter spp. are Gram-negative, oxidase-positive, microaerophilic bacteria, which 
typically have a curved shape and are between 0.5 and 5 µm long and 0.2 to 0.8 µm wide 
(Snelling et al., 2005). Motility, essentially rapid, darting movements within the mucosal 
layer of the gastrointestinal tract, is enabled by either a single polar flagellum at one end, or a 
single flagellum at each end of the bacterium. Campylobacter spp. belong to the class of ?-
proteobacteria, along with Arcobacter spp., Helicobacter spp., and Wolinella spp. In total, 
there are at least 18 species of Campylobacter (Humphrey  et  al.,  2007),  of  which  three  are  
especially important human pathogens; Campylobacter jejuni and C. coli typically cause 
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enteritis, and Campylobacter fetus is commonly known to cause bloodstream infections 
(Guerrant et al., 1978; Schmidt et al., 1980; Francioli et al., 1985; Gazaigne et al, 2008). 
 
C. jejuni and C. coli are thermophilic (optimal temperature for growth 42°C), whereas C. 
fetus is  not  generally  able  to  survive  at  42°C.  Campylobacter spp. do not utilize 
carbohydrates, which limits the use of biochemical tests in differential diagnostics between 
species. C. jejuni is usually able to hydrolyze hippurate, while C. coli is hippurate-negative, 
and a hippurate hydrolysis test can be performed to differentiate between C. jejuni and C. coli 
isolates, although misidentification may occur due to the existence of C. jejuni strains which 
lack the ability to hydrolyze hippurate (Totten et al., 1987; Siemer et al., 2005). Two separate 
Finnish studies suggest that the species of at least all the hippurate-negative isolates should be 
confirmed with PCR (Rautelin et al., 1999; Nakari et al., 2008). It has also been suggested 
that C. jejuni evolution has actually been quite rapid, and that the separation into C. coli and 
C. jejuni may have occurred as recently as within the past 12 000 years (Wilson et al., 2009), 
and this further highlights the close relatedness of the two species. The genomes of several C. 
jejuni strains have been sequenced (Parkill et al., 2000; Fouts et al., 2005; Hofreuter et al., 
2006; Lefébure & Stanhope, 2009). 
 
Campylobacter will here be used to refer to C. jejuni and C. coli, unless otherwise stated. 
2.2.2 Typing methods 
Phenotyping methods 
Before the development of reliable genotyping methods, phenotyping of C. jejuni and C. coli 
was usually performed by either of the two well-evaluated serotyping schemes: the Penner 
scheme (Penner & Hennessey, 1980) based on heat-stable (HS) antigens, and the Lior scheme 
(Lior et al., 1982), based on heat-labile (HL) antigens. The limitations of serotyping methods 
include high numbers of untypable strains and technical restrictions due to a lack of reagents 
and time-consuming and costly techniques. 
Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) is a genotyping method in which certain restriction 
enzymes enable digestion and subsequently separation of comparatively large DNA 
fragments through a gel matrix with a specific kind of gel electrophoresis; it has been of 
practical use in epidemiological studies (Yan et al., 1991). PFGE allows creation of genetic 
fingerprint patterns for comparing genotypes and is more discriminatory than is multilocus 
sequence typing (MLST) (Thakur et al, 2009), although comparing PFGE profiles from 
various laboratories has proven difficult. Another problem is that PFGE sometimes fails to 
type isolates (Wassenaar & Newell, 2000). In Finland, certain PFGE types predominate in 
human and chicken isolates (Hänninen et al., 2000). PFGE has been used successfully in 
many outbreak studies (Lehner et al., 2000; Olsen et al., 2001, Hänninen et al., 2003). 
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Multilocus sequence typing 
MLST is a genotyping method by which sequencing of seven housekeeping loci in the C. 
jejuni and C. coli genomes enable determination of the specific sequence type (ST) for a 
bacterial isolate (Maiden et al., 1998; Dingle et al., 2001). The seven housekeeping genes for 
the C. jejuni and C. coli MLST are aspA, glnA, gltA, glyA, pgm, tkt, and uncA, and the 
combined  allele  profile  of  these  genes  determine  the  ST  of  the  bacterium.  ST  clonal  
complexes  (ST  CCs)  consist  of  STs  with  at  least  four  alleles  in  common  with  the  founder  
genotype. The primary advantage of this sequence-based method, compared to PFGE, is that 
the results of different laboratories can be easily compared, and MLST data from different 
study groups are accessible and comparable online (http://pubmlst.org/campylobacter/). 
Other genotyping methods 
Flagellin typing (fla typing) is based on restriction fragment length polymorphism (RFLP) 
analysis or sequencing of the flagellin gene locus (Nachamkin et al., 1993a), with both highly 
conserved and variable regions (Meinersmann et al., 1997). The lack of international 
standardization and comparability between laboratories, however, restricts this method’s 
wider use (Wassenaar & Newell, 2000). More recently, sequence-based fla typing has 
become an additional part of MLST typing (Korczak et al., 2009). 
 
Ribotyping is a genotyping method involving agarose gel electrophoresis of digested 
genomic DNA and Southern blot hybridization with a probe specific for rRNA genes. The 
major disadvantage of this technique is its lower discriminatory power, compared to that of 
other genotyping techniques. 
 
Many other genotyping methods have been developed as well, but these methods are less 
widely used. 
2.3 Pathogenesis and virulence factors 
In order to successfully colonize the human intestinal tract, campylobacters need mechanisms 
for surviving in adverse environments and initiating chemotaxis, as well as structural and 
metabolic functions enabling bacterial motility (Nachamkin et al., 1993b), epithelial 
adhesion, cell invasion, iron acquisition, and toxin production (Ketley, 1997). Although 
several putative virulence and survival factors may be important for Campylobacter 
pathogenesis, the relevance of these particular genes and the proteins they encode for, 
considering the severity and outcome of campylobacteriosis, is generally poorly known. 
 
The relation between the pVir plasmid in C. jejuni and the severity of infection can serve to 
demonstrate the complexity of putative virulence factors. It has been suggested that the pVir 
plasmid encodes for proteins of a type IV secretion system, and that mutation of the virB11 
gene in the plasmid results in reduced adherence and invasion potential in vitro as well as less 
severe symptoms in vivo (Bacon et al., 2000). Studies have shown both an association (Tracz 
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et al., 2005), and a lack of association (Louwen et al., 2006) between the pVir plasmid and 
bloody diarrhea in C. jejuni enteritis. pVir has typically only been detected in a minority of 
the strains however (Tracz et al., 2005; Louwen et al., 2006), and the gene virB11 has in one 
study even been non-existent among C. jejuni strains (Talukder et al., 2008). This raises the 
question whether pVir can actually be considered an important virulence factor at all. 
 
The motility of Campylobacter is enabled by the flagella at the end of the bacterium, 
allowing it to “move with quite astonishing speed up and down mucus stands” (Lee et al., 
1986). The flagellar filament is composed of a major flagellin, FlaA, and a minor flagellin, 
FlaB, encoded by the genes flaA and flaB (Guerry et al., 1991; Alm et al., 1993). A special 
trait of ?-proteobacteria is that their flagella are glycosylated, and the flagella of 
Campylobacter have other functions in addition to enabling bacterial motility, such as the 
secretion of proteins which affect its virulence (Guerry, 2007). Recently, a link between C. 
jejuni flagella assembly and the biogenesis of lipooligosaccharide (LOS) on the outer core of 
C. jejuni emerged because the transferase Cj0256 modifies both these structures (Cullen & 
Trent, 2010). 
 
Some putative virulence proteins are secreted from the flagellar export apparatus, for 
example Campylobacter invasion antigen B (CiaB), encoded by the ciaB gene (Konkel et al., 
2004). C. jejuni isolates which lack the ciaB gene have non-invasive phenotypes (Konkel et 
al., 1999; Ziprin et al., 2001). On the other hand, a negative correlation has also been detected 
between ciaB and invasiveness (Fearnley et al., 2008). 
 
Lipopolysaccharides may be necessary for both adhesion to and the invasion of epithelial 
cells (Fry et al., 2000). Some LOS structures in C. jejuni resemble human neuronal 
gangliosides. This molecular mimicry has been hypothesized to lead to autoimmune 
responses in the human host, including the most important neurological complication after C. 
jejuni infection, the Guillain-Barré syndrome (GBS) (Mishu et al., 1993; Rees et al., 1995). 
The putative virulence genes cgtB (Gilbert et al., 2000) and wlaN (Linton  et  al.,  2000)  are  
involved in the biosynthesis of LOS, and may encode for ?-1, 3-galactosyltransferases with 
identical enzymatic activities (Linton et al., 2000; Gilbert et al., 2002). Evidence suggests that 
C. jejuni isolates with sialylated LOS are more invasive than nonsialylated isolates (Habib et 
al., 2009), and GBS-associated C. jejuni isolates have been associated with sialylated LOS 
(Koga et al., 2006). 
 
The gene cj0486 which encodes for a fucose permease (Stahl et al., 2011) may be associated 
with certain hyperinvasive C. jejuni strains (Fearnley et al., 2008). In addition, many other 
genes identified in the C. jejuni genome (Javed et al., 2010) are associated with metabolism 
and survival; their clinical relevance is unknown. 
 
Phospholipase A (PldA), encoded by gene pldA, has been suggested to have a role in the lysis 
of erythrocytes by C. coli, and it has therefore been proposed to be a putative virulence factor 
of Campylobacter (Grant et al., 1997). Further, an enterochelin binding lipoprotein, CeuE, 
which enables uptake of ferric siderophore, produced by other enteric bacteria, has been 
detected in C. coli (Richardson & Park, 1995). The Campylobacter enterochelin uptake (ceu) 
operon, ceuBCDE, encodes for a periplasmic binding-protein-dependent (PBT) system, 
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which is thought to be important for iron uptake especially during tissue invasion 
(Richardson & Park, 1995; Ketley, 1997), and the gene ceuE encodes for CeuE, an important 
part of the PBT system. 
 
Cytolethal distending toxin (CDT) is encoded by three genes, cdtA, cdtB, and cdtC, all of 
which have to function in order to enable the tripartite toxin to cause cell cycle arrest and 
distention of the cytoplasm in eukaryotic cells (Lara-Tejero & Galán, 2001). In a recent study 
from Bangladesh, CDT production was detected in almost all C. jejuni stool sample isolates 
(Talukder et al., 2008). 
 
There is strong data that ?-glutamyl transpeptidase (GGT), encoded by the ggt gene, has a 
role in glutathione and glutamine metabolism in C. jejuni (Hofreuter et al., 2008). GGT 
activity has been shown to be required for persistant colonization of the avian gut (Barnes et 
al., 2007), and a ggt mutant has been shown to have lesser colonization potential compared to 
the wild-type C. jejuni 81-176 strain in a murine model (Hofreuter et al., 2006). The major 
limitation in both avian and murine models, when studying the importance of putative 
virulence factors, is that only colonization can be reliably studied, as Campylobacter 
infection in these animals is typically either asymptomatic or atypical (Haddad et al., 2010). 
The presence of ggt has been shown to be less common in bovine C. jejuni strains, compared 
to avian or human C. jejuni strains (Gonzalez et al., 2009). 
 
Other proposed putative virulence factors include CheY (Yao et al., 1997), supposedly 
involved in bacterial chemotaxis and motility, PEB1 involved in adherence to, the invasion 
of, as well as colonization of HeLa cells (Pei et al., 1998), and the CadF protein has been 
proposed to be important for adhesion (Konkel et al., 1997). Alternate iron-acquisition 
systems have been described as well, for example chuABCD, and the FeoB protein, but the 
relevance of these systems for the uptake of iron by Campylobacter is still unclear. Possible 
virulence factors of C. jejuni and C. coli are shown in Table 1. 
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Table 1. Some putative virulence factors of C. jejuni and C. coli. 
gene virulence factor function reference 
    
cadF CadF adhesion Konkel et al., 1997 
cdtABC CDT bacterial toxin Johnson & Lior, 1988 
ceuBCDE PBT system iron acquisition Richardson & Park, 1995 
cheY CheY chemotaxis Yao et al, 1997 
chuA heme transport iron acquisition Ridley et al., 2006 
ciaB CiaB invasion Konkel et al., 1999 
cj0256 transferase modification of LOS 
and flagellae 
Cullen & Trent, 2010 
cj0486 putative sugar transporter metabolism Fearnley et al., 2008; 
Stahl et al., 2011 
iamA invasion-associated DNA 
marker 
invasion Carvalho et al., 2001 
cgtB, wlaN LOS adhesion, invasion Gilbert et al., 2000; 
Linton et al., 2000 
feoB FeoB iron acquisition Naikare et al., 2006 
flaA, flaB flagellum motility, secretion Guerry et al., 1991 
ggt GGT metabolism, 
colonization 
Hofreuter et al., 2006 
pldA PldA erythrocytolysis Grant et al., 1997 
virB11 pVir plasmid adhesion, invasion Bacon et al, 2000 
2.4 Epidemiology 
2.4.1 General aspects 
Campylobacter colonizes the intestinal tract of many different animals, including cattle, cats, 
dogs, poultry, sheep, swine, and many different species of wild birds, and although this 
colonization rarely causes any symptoms in the animal hosts, C. jejuni in particular is a 
considerable human pathogen, and the incidence of infections has been increasing in many 
industrialized nations (Olson et al., 2008). C. jejuni infection is common worldwide, with an 
estimated incidence rate of approximately 500 to 850 infections/100 000 in the USA (Samuel 
et al., 2004). This conforms to its estimated incidence in the UK, as the incidence calculated 
on the basis of reported human cases in 2004 was 84 infections/100,000 (EFSA, 2005), and 
an English study suggested that the actual incidence of Campylobacter infection may be 
almost 10-fold that, or higher (Wheeler et al., 1999). Campylobacter is the most commonly 
reported gastrointestinal pathogen in the European Union (EFSA, 2005; EFSA, 2009). It is 
also the most common zoonosis in the EU. 
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Figure 1 Reported EU cases of Campylobacter infection 1999-2007 (EFSA, 2009). 
 
Small children and young adults are especially prone to Campylobacter infection (Blaser, 
1997; Friedman et al., 2004; Samuel et al., 2004). Men are typically over-represented in 
patient groups (Butzler & Skirrow, 1979; Samuel et al., 2004; Strachan et al., 2008), and this 
trend can also be noted at the national level in Finland based on the annual surveillance 
statistics of the National Institute for Health and Welfare (www3.ktl.fi/stat/). 
 
The seasonal variation of Campylobacter infection has been noted in many studies, as 
typically a peak in Campylobacter infection incidence occurs in developed countries in the 
northern hemisphere during June-August (Butzler & Skirrow, 1979; Rautelin & Hänninen, 
2000; Samuel et al., 2004). This seasonal peak is also evident in the most recent EFSA report 
(EFSA, 2009). 
2.4.2 Sources of infection 
Eating or handling raw or inadequately cooked poultry meat is an important risk factor for 
campylobacteriosis (Harris et al., 1986; Neal & Slack, 1997; Studahl & Andersson, 2000). 
Eating seafood (Harris et al., 1986; Friedman et al., 2004), pork with bones (Studahl & 
Andersson, 2000), or eating either poultry or non-poultry meat at a restaurant (Friedman et 
al., 2004), eating at barbecues (Kapperud et al., 1992), eating chicken regularly or outside the 
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home only (Tam et al., 2009), as well as drinking unpasteurized milk (Studahl & Andersson, 
2000; Friedman et al., 2004) are also documented sources of infection. Drinking water from 
dug wells has been a risk factor (Schönberg-Norio et al., 2004), and because many 
Campylobacter species are commensal organisms of birds, fecal contamination of surface 
water by birds can increase the risk for subsequent human infection (Broman et al., 2002). 
Further, domestic pet contact may be associated with increased risk for Campylobacter 
infection (Kapperud et al., 1992; Friedman et al., 2004); especially contact with a dog puppy 
seems to be associated with Campylobacter infection in infants (Tenkate & Stafford, 2001). 
 
The infective dose of Campylobacter is extremely low; as few as 500 to 800 cells can cause 
infection (Robinson, 1981; Black et al., 1988). Campylobacter is capable of transition into a 
“viable, but nonculturable state” under adverse environmental conditions (Rollins & Colwell, 
1986), swimming in natural sources of water is a risk factor for Campylobacter infection 
(Schönberg-Norio et al., 2004), and the pathogen can even survive on fresh produce long 
enough to indirectly cause infection in humans (Kärenlampi & Hänninen, 2004). A recent 
British  study  attributed  the  vast  majority  of  C. jejuni infections in humans to chicken and 
cattle sources (Wilson et al., 2008). 
2.4.3 Geographical aspects of Campylobacter infection 
Considerable variation exists in the distribution of human Campylobacter infection incidence 
among European countries. For example, incidence rates for the Czech Republic versus Spain 
or Estonia suggest that rate-differences between European countries might even exceed 20-
fold (EFSA, 2005). This can in part be explained by differences in their notification systems, 
such as improvements in the system showed in Austria in 2004 (EFSA, 2005). In Spain, only 
hospitalized cases are notifiable (EFSA, 2005), and some countries like Greece or Portugal 
have no surveillance systems at all (EFSA, 2009). Considerable variation exists in origin of 
confirmed Campylobacter infections as well, with the only countries in which imported cases 
of campylobacteriosis predominate over domestic cases are Finland, Sweden, and Norway 
(EFSA, 2009). Reported broiler-flock prevalences of Campylobacter have been consistently 
low in these three Scandinavian countries (EFSA 2005, EFSA 2009). 
 
Many notable differences appear in Campylobacter epidemiology between developed and 
developing countries (Table 2). First, average age of the infected patient is lower in 
developing countries (Blaser et al., 1983; Blaser, 1997). Second, the incidence of 
Campylobacter infection, especially for infants, seems to be significantly higher, with 
campylobacteriosis even suggested as being a hyperendemic infection in developing 
countries (Coker et al., 2002). Third, in developing countries, after continuous or repeated 
infections, populations seem to develop some degree of immunity to campylobacteriosis 
(Blaser, 1997). Fourth, asymptomatic infections are known to occur in developing countries 
(Glass et al., 1983), but are very uncommon in developed countries (Blaser et al., 1979; 
Blaser et al., 1983).  
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Table 2. Comparison of characteristics of C. jejuni infections in developed and developing countries 
(adapted from Blaser, 1997). 
Characteristic Developed countries Developing countries 
   
“Infections/lifetime” (estimate 
according to Blaser) 
Very few (“0-1”) Numerous (“>5”) 
   
Age group mostly affected “Young adults” “Children <2 years old” 
   
Typical diarrhea “Inflammatory diarrhea” “Simple diarrhea” 
   
“Widespread immunity 
among adults” 
“Absent” “Present” 
 
2.4.4 Outbreaks 
Campylobacter infections in humans are mostly sporadic, and those infected during 
Campylobacter outbreaks are few compared to the total number of patients diagnosed with 
campylobacteriosis. For example, a study which summarized findings from Communicable 
Disease Surveillance Centre reports noted that between 1992 and 1994, 706 patients were 
diagnosed with a Campylobacter infection, attributable to one of the 21 outbreaks in England 
and Wales with Campylobacter implicated as the causative organism (Frost et al., 2002). This 
would suggest that less than 0.5% of Campylobacter infections are related to outbreaks. 
 
Outbreaks have usually been attributed to unpasteurized milk (Robinson & Jones, 1981; 
Lehner et al., 2000; Schildt et al., 2006) or tapwater, and during the last three decades several 
water-borne outbreaks have caused widespread infection in certain geographically distinct 
areas (Mentzing, 1981; Palmer et al., 1983; Engberg et al., 1998; Kuusi et al., 2004; Kuusi et 
al., 2005). 
 
Water-borne outbreaks have typically been associated with groundwater plants, contaminated 
by Campylobacter due to heavy rainfalls (Hänninen et al., 2003). In addition, in Finnish 
outbreak studies, leaks or failure in well pipes or cross-connections between sewage- and 
drinking-water pipelines are probable reasons for water supply contamination (Rautelin et al., 
1990; Laine et al., 2010). 
2.5 Diagnostic methods 
Four important types of diagnostic methods allow detection of Campylobacter infection: 
stool and blood culture, serum antibody detection, antigen detection from stools, and DNA-
based methods. 
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Since the development of a selective growth medium for Campylobacter by Skirrow (1977), 
bacterial culture on different selective media, especially charcoal-based, has been an efficient 
method for detecting and isolating the important stool pathogens C. jejuni and C. coli (Endtz 
et al., 1991b; Kulkarni et al., 2002). Although filtration has been proposed as a cost-effective 
alternative  to  culture  on  selective  media  (Lastovica  &  le  Roux,  2000),  it  still  seems  to  be  
relatively insensitive and a more difficult method than either selective culture or PCR 
identification (Kulkarni et al., 2002).  
 
Serodiagnosis of Campylobacter infection is enabled by use of an enzyme-linked 
immunosorbent assay (ELISA) to detect specific serum antibodies of the IgA, IgG, and IgM 
classes.  To  maximize  the  specificity  of  serological  diagnosis,  elevated  titers  of  at  least  two 
immunoglobulin classes should probably be chosen for diagnosis of a recent Campylobacter 
infection (Taylor et al., 2004), although this typically results in a loss of sensitivity. In 
addition, paired serum samples showing at least four-fold antibody titer changes indicate an 
acute Campylobacter infection (Rautelin & Kosunen, 1987). IgG antibodies usually remain 
elevated for longer periods, up to several months in some patients (Kaldor et al., 1983; 
Rautelin & Kosunen, 1987), and determining the IgG titer alone is insufficient for diagnosis 
of an acute infection (Kaldor et al., 1983; Rautelin & Kosunen, 1987; Taylor et al., 2004). On 
the other hand, elevated antibody titers of IgA and IgM classes have commonly been 
detectable in patients with an active Campylobacter infection (Kaldor et al., 1983; Rautelin & 
Kosunen, 1987; Black et al., 1988; Strid et al., 2001). 
 
Enzyme immunoassay-based stool antigen tests have been developed for rapid detection of 
Campylobacter infection, but clinical use of rapid antigen tests is limited because of low 
sensitivity (Tissari & Rautelin, 2007), and the need for later verification of negative test 
results (Hindiyeh et al., 2000; Tissari & Rautelin, 2007). 
 
PCR assays enable rapid identification of C. jejuni and C. coli to species level (Linton et al., 
1997; Denis et al., 1999; Gilbert et al., 2003), but the cost and workload of PCR assays, as 
well as the lack of a bacterial isolate for further analyses, have been pointed out as 
disadvantages, compared to culture techniques (Kulkarni et al., 2002). 
 
Multiplex PCR assays allow the exact identification of several enteric pathogens at the same 
time.  A  study  in  which  different  PCR  assays  were  compared  for  sensitivity  and  specificity  
found that most of the methods were reasonably trustworthy and performed equally 
(Debruyne et al., 2008). Recently, stool culture was shown to be clearly less sensitive to 
multiplex-PCR (Bessède et al., 2011). 
 
In addition to these methods, recent results indicate that matrix-assisted desorption ionization 
time-of-flight mass spectrometry (MALDI-TOF MS), available in a rapidly increasing 
number of clinical laboratories, should be a reliable and sensitive method for identifying 
Campylobacter isolates (Martiny et al., 2011). 
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2.6 Antimicrobial susceptibility 
2.6.1 Antimicrobial susceptibility testing 
Three commonly used methods are suitable for determining whether a bacterial isolate is 
susceptible or resistant to a certain antimicrobial agent: minimal inhibitory concentration 
(MIC) testing which can be performed by either an agar or a broth dilution susceptibility test, 
disk  diffusion,  and  the  combination  of  the  disk  diffusion  method  and  the  exact  dilution  
method, the E-test. 
 
The  MIC  value  of  an  antimicrobial  agent  is  defined  as  the  lowest  concentration  of  an  
antimicrobial agent that prevents visible growth of a microorganism in an agar or broth 
dilution-susceptibility test. If the E-test method is used, the corresponding value can be seen 
at  the  point  where  the  zone  of  growth  inhibition  intersects  the  strip  with  a  gradient  of  the  
antimicrobial  agent  tested  (PDM Epsilometer,  AB Biodisk,  Solna,  Sweden).  While  an  agar  
dilution method, using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood 
and C. jejuni ATCC 33560 as a quality-control strain (McDermott et al., 2004), has been 
developed for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem, and 
been recognized by the Clinical and Laboratory Standards Institute (CLSI) as the standard 
antimicrobial susceptibility testing method for thermophilic Campylobacter (CLSI, 2005), the 
less time-consuming and less expensive method of broth dilution is an alternative for 
determining MIC values (Luber et al., 2003). For broth dilution testing of Campylobacter, 
Mueller-Hinton broth with 2.5 to 5% lysed horse blood has been approved for determining 
MIC values (CLSI, 2006). 
 
A disk diffusion method for determining antimicrobial susceptibility of Campylobacter 
involves use of Mueller-Hinton agar with 5% sheep blood inoculated with a direct colony 
suspension of the test organism - equivalent to a 0.5 McFarland standard - and paper discs 
containing specific concentrations of the antimicrobial agent are applied to the surface of the 
agar. After this, incubation for 24 to 48 hours at optimal temperature and atmosphere follows 
(CLSI, 2006). The antimicrobial agent diffuses into the agar, inhibiting the growth of bacteria 
which are susceptible to the antimicrobial agent, and this can be seen as a zone of inhibition 
around each disc. 
 
In addition, study of plasmids or genes associated with resistance can aid in understanding of 
antimicrobial resistance mechanisms. 
2.6.2 Antimicrobial susceptibility and resistance among Campylobacter 
Macrolides and fluoroquinolones have been the primary drugs of choice for 
campylobacteriosis (Aarestrup & Engberg, 2001), but increasing antimicrobial resistance, 
especially to fluoroquinolones, is becoming an important health issue. The mechanisms by 
which Campylobacter develops resistance against fluoroquinolones and macrolides are well 
known. Fluoroquinolone resistance is attributed to mutations in genes encoding DNA gyrase 
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(gyrA), more specifically at positions Thr-86, Asp-90, and Ala-70 (Wang et al., 1993; Ge et 
al., 2005). Macrolide resistance is mostly considered to be due to mutations in the 23S rRNA 
gene (Gibreel et al., 2005). Another mechanism with a role in the development of macrolide 
resistance in Campylobacter is the Campylobacter multidrug efflux pump (CmeABC) 
(Cagliero et al., 2005; Gibreel et al., 2007); modifications in the ribosomal proteins L4 and 
L22 may also affect the susceptibility to macrolides (Cagliero et al., 2006). 
 
In the beginning of the 1990’s, an increase in quinolone resistance in human Campylobacter 
isolates in the Netherlands coincided with increased use of fluoroquinolones in both human 
and veterinary medicine (Endtz et al., 1991a). Shortly thereafter, in Finland, and later in other 
countries, many separate reports confirmed that quinolone resistance had increased 
significantly within only one decade (Rautelin et al., 1991; Reina et al., 1994; Murphy et al., 
1996; Smith et al., 1999; Gupta et al., 2004). This, however, has not been the case among 
domestically acquired infections in Finland (Rautelin et al., 2003; Schönberg-Norio et al., 
2006), where fluoroquinolones are not used in poultry production (Hänninen et al., 1999; 
Rautelin & Hänninen, 2000). In fact, few domestic Campylobacter isolates in Finland are 
resistant to fluoroquinolones, while the majority of isolates originating from countries with a 
high prevalence of quinolone resistance, for example Spain or Thailand, are resistant to 
fluoroquinolones (Rautelin & Hänninen, 2000). 
 
Following the rapid emergence of fluoroquinolone resistance among Campylobacter, interest 
has increased in studying whether or not the decreased antimicrobial susceptibility affects the 
clinical outcome of disease. Results have been contradictory (Table 3). 
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Table 3. Impact of ciprofloxacin resistance on clinical outcome of Campylobacter infection. 
Country Time period Isolates 
studied 
(N) 
Ciprofloxacin 
resistance 
Conclusion Reference 
      
Denmark 
 
1996-2000 3471 22% Quinolone resistance 
associated with increased 
risk for adverse events  
Helms et al., 
2005 
      
USA 
 
1998-1999 858 11% Longer-lasting diarrhea 
among patients with 
ciprofloxacin-resistant 
isolates 
Nelson et al., 
2004 
      
England and 
Wales 
 
2000-2001 3489 19% No difference in hospital 
admission or mean length 
of illness 
The 
Campylobacter 
Sentinel 
Surveillance 
Scheme 
Collaborators, 
2002 
      
Re-analysis 
of studies 
from USA 
and UK 
1998-2001   Infections caused by 
fluoroquinolone-resistant 
Campylobacter not more 
severe than those caused 
by susceptible isolates 
Wassenaar et 
al., 2007 
      
Australia 2001-2002 585 2% Infection with 
ciprofloxacin-resistant C. 
jejuni not resulting in a 
more severe illness 
Unicomb et al., 
2006 
      
Denmark 2001-2002 467 18% Patients with quinolone-
resistant C. jejuni 
infections with longer 
mean duration of illness 
Engberg et al., 
2004 
 
Macrolide resistance is typically detected in C. coli strains, possibly because tylosin is a 
growth-promoter in pigs in some countries (Engberg et al., 2001; Gibreel et al., 2006). 
Interestingly, macrolide resistance is not usually detected in Finland (Rautelin et al, 2003), 
and the situation appears to be similar in Sweden (Rönner et al., 2004) and Japan (Gibreel et 
al., 2006). 
 
When determining the therapeutic effect of an antimicrobial agent against a certain micro-
organism, one problem is the lack of international standards and guidelines (Kahlmeter et al., 
2003). The clinical breakpoints for ciprofloxacin and erythromycin are available for 
comparison from two major committees, the CLSI (CLSI, 2009) in the USA and the 
EUCAST (www.eucast.org) in Europe. For ciprofloxacin, a Campylobacter strain is 
considered resistant if the MIC-value is ?4 µg/ml according to CLSI guidelines, and for 
erythromycin, the breakpoint for resistance is ?32 µg/ml. These breakpoints are somewhat 
higher than the EUCAST guidelines: for ciprofloxacin MIC-values ?2 µg/ml, and for 
erythromycin MIC-values ?8 µg/ml. In addition to clinical breakpoints, the EUCAST also 
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monitors resistance development, which is expressed with epidemiological cut-off values 
(Kahlmeter et al., 2003; www.eucast.org). 
2.7 Clinical aspects of Campylobacter infection 
2.7.1 Enteritis 
The typical clinical signs after ingestion, and subsequent intestinal colonization of C. jejuni 
or C. coli indicate an inflammatory response in the affected human host; endoscopy may 
reveal macroscopically visible enteritis affecting the jejunum, ileum, and colon (Blaser et al., 
1980; Blaser & Reller, 1981). The incubation period is normally 3 to 5 days but can 
sometimes be shorter or significantly longer, even up to 10 days (Butzler & Skirrow, 1979; 
Butzler, 2004). Nonspecific prodromal symptoms, for example headache, myalgia, and fever, 
may precede the diarrheal illness and last approximately one day (Blaser, 1997). Watery 
diarrhea, fever, and abdominal cramps and pain which sometimes mimic those of acute 
appendicitis, are common features of Campylobacter enteritis, and blood and leukocytes in 
the stools are relatively frequent, as well (Blaser, 1997; Rautelin & Hänninen, 2000; Butzler, 
2004). The diarrheal phase usually lasts for a few days, and while patients often recover from 
the disease within a week, the symptoms can sometimes be prolonged or re-appear (Blaser, 
1997; Rautelin & Hänninen, 2000; Butzler, 2004). The timing of clinical symptoms, in 
relation to stool culture and serology, is presented in Figure 2. 
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Figure 2 Timeline of an acute Campylobacter infection. 
 
Patients with a clinical picture involving bloody stools or vomiting are likely to have a longer 
duration of illness and may require hospital treatment more often than others (Gillespie, et al., 
2006). 
2.7.2 Bacteremia 
As noted by Butzler (2004), Vibrio fetus (C. fetus) was the first Campylobacter species to be 
detected and identified from human blood cultures; Vinzent et al. (1947) were able to isolate 
the pathogen from a pregnant woman well before the ‘related vibrios’ were recognized as 
human pathogens. However, it was later confirmed that C. jejuni and C. coli are  also  
important pathogens causing Campylobacter bacteremia (Blaser et al., 1986; Skirrow et al., 
1993). In fact, many studies have shown that the thermophilic Campylobacter species are 
isolated more often than C. fetus from human blood samples (Skirrow et al., 1993; 
Schønheyder et al., 1995; Nielsen et al., 2010a; Fernández-Cruz et al., 2010). Although 
Campylobacter are not commonly associated with invasiveness, it has been estimated that 
bacteremia can be detected in approximately 1% of patients with Campylobacter infection 
(Samuel et al., 2004). On the other hand, as blood cultures are usually taken only from those 
with febrile gastroenteritis who have been referred to, or seek hospital care, the actual 
incidence of Campylobacter bacteremia may be significantly higher. 
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Patients with Campylobacter bacteremia typically experience the same array of symptoms as 
do patients with uncomplicated enteritis: e.g. fever, malaise, and gastrointestinal symptoms, 
although diarrhea sometimes occurs in only about one third of patients (Pigrau et al., 1997; 
Pacanowski et al., 2008). Noteworthy also is that many Campylobacter bacteremia patients 
may have concomitant cellulitis, and although skin infection mostly seems to be attributed to 
C. fetus (Pigrau et al., 1997; Pacanowski et al., 2008; Gazaigne et al, 2008), some report 
cellulitis as occurring concurrently with C. jejuni bacteremia (Tee & Mijch, 1998; Monselise 
et al., 2004). 
 
Differences between clinical disease caused by C. fetus or by either C. jejuni or C. coli 
include the findings that C. fetus infection is not commonly associated with enteritis and 
diarrhea, and patients with C. fetus infection are often elderly or immunocompromised 
(Guerrant et al., 1978; Schmidt et al., 1980; Francioli et al., 1985; Gazaigne et al, 2008). In 
recent European studies performed at hospitals in France and Spain, the mortality of 
Campylobacter bacteremia patients has been 10 to 15% (Pigrau et al., 1997; Pacanowski et 
al., 2008; Fernández-Cruz et al., 2010), while a Danish study found mortality to be as low as 
4% (Nielsen et al., 2010a). Campylobacter bacteremia mortality data are presented in Table 
4. 
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Table 4. Species distribution and mortality rates from Campylobacter bacteremia studies (adapted 
data from Fernández-Cruz et al., 2010). 
Location Study 
period 
N of 
patients 
Campylobacter 
species 
Mortality Reference 
      
England and 
Wales 
1981-
1991 
394 C. jejuni/coli 89% NA Skirrow et al., 1993 
      
South Africa 1991-
1994 
19 C. jejuni 100% 16% Reed et al., 1996 
      
Australia 1985-
1995 
21 C. jejuni 100% 14% Tee & Mijch, 1998 
      
Barcelona, Spain 1979-
1996 
58 C. jejuni/coli 83% 10.5% Pigrau et al., 1997 
      
Paris, France 2000-
2004 
183 C. jejuni/coli 39% 15% Pacanowski et al., 2008 
      
Denmark 1995-
2004 
46 C. jejuni/coli 91% 4% Nielsen et al., 2010a 
      
Madrid, Spain 1985-
2007 
68 C. jejuni/coli 78% 15% Fernández-Cruz et al., 2010 
 
Well-characterized clinical materials for which C. jejuni bacteremia isolates are available are 
scarce, and therefore information regarding the possible differences in the virulence factor 
profiles of blood and stool isolates is limited. Nielsen et al found no association between the 
virulence genes iam, cdtB, capA, or virB, and C. jejuni blood isolates, as compared to stool 
culture isolates (Nielsen et al., 2010b). 
2.7.3 Other extra-intestinal infections 
In addition to bacteremia, other extra-intestinal infection foci for C. jejuni/ coli include 
cellulitis (Tee & Mijch, 1998; Monselise et al., 2004), cholecystitis (Blaser et al., 1986), 
meningitis (Blaser et al., 1986; Goossens et al., 1986), peritoneal infection, and abscesses, as 
well  as  urinary  tract  infection  (Blaser  et  al.,  1986).  In  addition,  respiratory  tract  infections  
occur in immunocompromised patients with bacteremia (Tee & Mijch, 1998; Fernández-Cruz 
et al., 2010), although microbiological verification is lacking. Increased bacterial virulence, 
such as serum resistance, may need to occur before Campylobacter causes extraintestinal 
infection in normal, healthy human hosts (Blaser et al., 1986). 
2.7.4 Guillain-Barré syndrome 
As early as in 1982, two separate case reports suggested a link between an acute 
inflammatory polyneuropathy, termed GBS, and C. jejuni infection  (Rhodes  & Tattersfield,  
1982;  Molnar  et  al.,  1982).  GBS  has  since  been  shown  to  be  a  severe  complication  of  C. 
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jejuni infection (Mishu et al., 1993; Rees et al., 1995), and the estimated risk for GBS after 
Campylobacter infection is approximately 1-3/10 000 cases of campylobacteriosis (McCarthy 
& Giesecke, 2001; Tam et al., 2006). 
 
GBS is an autoimmune condition, in which the patients develop antibodies against 
gangliosides, most typically GM1, resulting in axonal degeneration through either 
demyelinization or direct axonal damage. Carbohydrate mimicry between GM1 and C. jejuni 
LOS leading to the development of such cross-reactive antibodies has been shown to occur 
under experimental conditions in rabbits (Yuki et al., 2004). Some strains of C. jejuni have 
sialylated LOS (Parker et al., 2005). These sialylated carbohydrates closely resemble some of 
the human gangliosides (Gilbert et al., 2002). Some C. jejuni serotypes have been associated 
with the development of GBS, particularly Penner serotype O:19 (Allos et al., 1998). 
Sialylated LOS is more prevalent than nonsialylated LOS in GBS-associated C. jejuni strains 
(Koga et al., 2006), but not all C. jejuni isolated from patients who developed GBS have 
sialylated LOS (Godschalk et al., 2007). Certainly, many other bacterial and host factors 
might affect the pathogenesis of GBS, as molecular mimicry at present insufficiently explains 
why certain patients develop GBS. 
2.7.5 Other sequelae 
Antecedent Campylobacter infection is considered a risk factor for reactive arthritis (Hannu 
et al., 2002; Locht & Krogfelt, 2002). The prevalence of reactive arthritis among patients 
examined within a median of 11 weeks after the onset of Campylobacter infection was 7% 
(Hannu et al., 2002). However, self-reported musculoskeletal symptoms are more prevalent, 
and studies have shown that between 16% and 39% of patients, after Campylobacter 
infection, have reported joint symptoms which could indicate arthritis or tendinitis (Bremell 
et al., 1991; Locht & Krogfelt, 2002; Schönberg-Norio et al., 2010). In one study, a longer 
duration of diarrhea was significantly associated with later arthralgia (Locht & Krogfelt, 
2002). Antimicrobial treatment does not prevent the development of reactive joint symptoms 
(Locht & Krogfelt, 2002; Schönberg-Norio et al., 2010). 
 
An association is known between bacterial enteritis and the development of irritable bowel 
syndrome (IBS), and in studies where Campylobacter infection has been prevalent, the 
incidence of IBS as a post-infectious complication is estimated to be between 4 and 13% 
(Rodríguez et al., 1999; Spiller, 2007). 
2.7.6 Treatment 
It is generally accepted that Campylobacter enteritis is a self-limited disease which resolves 
spontaneously in the majority of infected patients, and that antimicrobial treatment should be 
reserved primarily for immunocompromised individuals and patients with severe symptoms 
(Blaser, 1997; Rautelin & Hänninen, 2000; Butzler, 2004). For a long period of time, 
fluoroquinolones were considered the appropriate treatment for campylobacteriosis, but due 
to the increasing fluoroquinolone resistance which has developed rapidly in many parts of the 
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world, these antimicrobials are no longer considered to be optimal empirical treatment of 
Campylobacter infections (Allos, 2001). Traditionally, erythromycin has been regarded as a 
primary choice of treatment for campylobacteriosis, and has been presented as the most 
favorable option for treating uncomplicated intestinal illness (McNulty, 1987). Although 
some studies have suggested that antibiotic treatment shortens the duration of illness 
(Salazar-Lindo et al., 1986; Kuschner et al., 1995), double-blind placebo-controlled trials 
have shown that differences in the duration of symptoms are minimal between the patients 
treated with erythromycin and those who receive placebo (Anders et al., 1982; Mandal et al., 
1984).  In  addition,  a  recent  meta-analysis  showed that  the  beneficial  effect  of  antibiotics  is  
limited, possibly only shortening the duration of gastrointestinal symptoms by little more 
than a day (Ternhag et al., 2007). In a recent Finnish study, appropriate antimicrobial therapy, 
based on the MIC values of the isolates, shortened the duration of illness only when initiated 
within two days after onset of symptoms (Schönberg-Norio et al., 2010). However, several 
studies have clearly shown that treatment with erythromycin effectively eradicates 
Campylobacter from patients’  stools  (Anders  et  al.,  1982;  Mandal  et  al.,  1984;  Williams  et  
al., 1989). 
 
When considering antimicrobial treatment for Campylobacter bacteremia, antimicrobial 
susceptibility of the blood culture isolate is of even greater importance and should naturally 
be taken into consideration when the therapy is planned. The beneficial effect of appropriate 
antimicrobial treatment on the outcome of Campylobacter bacteremia has been either evident, 
particularly for species other than C. fetus (Pacanowski et al., 2008), or non-existent 
(Fernández-Cruz et al., 2010). 
 
While not regarded as primary antimicrobial agents for campylobacteriosis treatment, 
carbapenems may be an alternative treatment for severe Campylobacter infection, based on 
susceptibility-testing results (Pacanowski et al., 2008; Fernández-Cruz et al., 2010). Even 
multi-drug-resistant Campylobacter isolates are still susceptible to carbapenems, at least in 
vitro (Lehtopolku et al., 2010). In Finland, C. jejuni and C. coli have been highly susceptible 
to aminoglycosides (Rautelin et al., 1991; Lehtopolku et al., 2010). Further, based on the 
susceptibility patterns of the isolates tested, clindamycin (Wagner et al., 2003), tetracyclines 
(Wagner et al., 2003), and tigecycline (Lehtopolku et al., 2010) are possible alternatives for 
antimicrobial therapy of Campylobacter infection. 
2.7.7 Immunological aspects 
Several immunological factors affect both the susceptibility of the human host to 
Campylobacter infection, as well as its outcome and course. 
 
Innate immunity to Campylobacter infection can be divided into the defense mechanisms of 
the gastrointestinal tract and those defenses present in the intestinal submucosa and systemic 
circulation (Iovine, 2008). The gastrointestinal tract is an important first-line defense barrier, 
and important innate immune defenses include salivary nitrite, gastric acid, the microbiome 
of the large intestine, mucins, defensins, Toll-like receptors (TLRs), and, to a certain degree, 
bile (Iovine, 2008). 
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Interestingly, bile has triggered CiaB expression in C. jejuni in vitro (Rivera-Amill  et  al.,  
2001). On the other hand, Campylobacter is generally bile-resistant, and cholecystitis 
sometimes occurs as a complication during or after campylobacteriosis. 
 
Lipopolysaccharides are known ligands to TLR2 and TLR4 on the surface of dendritic cells 
(DCs) (Moll, 2003). C. jejuni activates DCs through TLR4 signalling (Rathinam et al., 2009), 
and sialylation of LOS may enhance this activation (Kujif et al., 2010), and possibly even 
lead to the development of anti-ganglioside antibodies (Kujif et al., 2010), which are 
associated with the neurological complication GBS (Yuki et al., 2004). 
 
The inflammatory response leading to neutrophil and macrophage recruitment is the basis for 
the systemic defensive mechanisms of the innate immunity mechanism in the human host. 
Proinflammatory  responses  of  cytokines  and  chemokines  as  well  as  phagocyte  recruitment  
and the activation of complement are essential innate immunity defense mechanisms (Janssen 
et al., 2008). Very few studies show any association between Campylobacter bacteremia and 
sensitivity to normal human serum (NHS); C. fetus is essentially serum-resistant, while the 
serum susceptibility of C. coli and C. jejuni varies considerably (Blaser et al., 1985; 1986). 
The complement-mediated killing of serum-susceptible isolates is important for restricting 
the access of pathogens as well as of commensal organisms to the bloodstream; however, C. 
jejuni blood isolates are not always particularly serum-resistant (Blaser et al., 1985). 
Sialylated LOS may be important for the development of serum resistance in C. jejuni 
(Guerry et al., 2000), while another group speculates that LOS plays a role in resisting some 
defensins and proteins, and that the capsule would instead be associated with serum 
resistance (Keo et al., 2011). 
 
In addition to the diagnostic usefulness of understanding the activation of humoral immune 
responses during and following Campylobacter infection, the role of the adaptive immune 
system in disease severity and the development of cross-reactive immunity at an individual 
level has been studied (Janssen et al., 2008). Vast epitopic variation in immunogenic 
Campylobacter surface components such as flagellin, the major outer membrane protein 
(MOMP), capsule structures, and LOS, is mostly attributed to the fact that these antigenic 
regions are particularly poorly conserved (Havelaar et al., 2009). Due to the antigenic 
diversity, it is therefore probable that although the presence of Campylobacter-specific 
antibodies indicates exposure to infection, the possible protection provided by these 
immunoglobulins is mostly limited to homologous Campylobacter strains (Havelaar et al., 
2009). Hence, it seems that repeated exposure to heterologous strains may be a requirement 
for development of cross-reactive immunity. 
 
When considering the immunological importance of various immunoglobulins, it is worth 
noting that empirical evidence for at least two major classes of immunoglobulins, IgA and 
IgG, exists. The protective effect of IgA, and of secretory IgA (sIgA) in particular, has been 
shown (Mégraud et al., 1990). Furthermore, children with elevated IgG levels in developing 
countries are less likely to develop the more severe symptoms like bloody diarrhea (Blaser et 
al., 1985; Blaser et al., 1986; Janssen et al., 2008). 
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In accordance with differences between the characteristics of C. jejuni infection in different 
parts of the world (Table 2), findings reflecting the development of partial immunity against 
this heterogenous species have been presented in a study by Miller et al., in which common 
serotypes were over-represented among patients under age 40, while uncommon serotypes 
were over-represented among the older (Miller et al., 2005). 
2.7.8 General health burden and cost 
Among estimates of the costs and health care burden due to campylobacteriosis, in Sweden 
(population approximately 8 million) the total cost, with both direct healthcare costs and 
indirect, patient-, and loss-of-earning-related costs included, came to as much as 179 to 352 
million Swedish crowns (data from Government Offices of Sweden). This estimate is based 
on  a  prevalence  multiplier  of  9.02,  and  the  direct  healthcare  costs  accounted  for  
approximately 15% of total cost. The cost of acute campylobacteriosis to patients and the 
health services in the UK, excluding the costs of post-infectious complications, was estimated 
to be around 20 million UK pounds (personal communication, Tam CC, 2012). An earlier 
estimate from the UK attributed roughly 10% of the total cost of intestinal infectious diseases 
(743 million UK pounds) to Campylobacter infection, indicating that the most significant 
proportion of the socio-economic impact of bacterial enteropathogens was due to 
campylobacteriosis (Roberts et al., 2003). 
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3. Aims of the study 
Bacterial traits which could lead to a more severe outcome of Campylobacter infection are 
not well known. Although experimental studies have proposed a number of possible 
virulence factors as important for colonizing and invading the human host, the need is evident 
for studies with non-selected clinical materials with patient data to study these findings’ 
relevance. The aim of this PhD thesis was to clarify whether factors, involving patients’ and 
bacterial characteristics, are important for development of a more severe Campylobacter 
infection. The specific aims of the study were: 
 
1. To study whether ciprofloxacin-resistant C. jejuni or C. coli isolates cause more 
severe disease. 
 
2. To screen for putative virulence factors of C. jejuni isolates  and  to  study  their  
possible association with disease outcome, or with severity of symptoms. 
 
3. To characterize C. jejuni and C. coli bacteremia patients as well as the course and 
outcome of the disease. 
 
4. To study the bacterial characteristics of C. jejuni blood culture isolates, and more 
specifically; 
 
whether certain MLST CCs are associated with bacteremia, 
 
whether serum resistance is needed for C. jejuni to cause bacteremia, 
 
whether sialylated LOS is prevalent among C. jejuni bacteremia 
isolates, 
 
and whether any of these bacterial characteristics are associated with C. 
jejuni bacteremia in certain patient subgroups, for example, those with 
severe underlying diseases.  
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4. Materials and methods 
4.1 Patient data 
4.1.1 Campylobacter enteritis patients (I, II) 
Patients from the Helsinki-Uusimaa region for whom Campylobacter-positive stool samples 
were  detected  at  Helsinki  University  Central  Hospital  Laboratory  (HUSLAB)  from  July  1  
through December 31, 2006 were asked to participate in the study. Questionnaires, along with 
information about the study, went to the physicians who had referred the patients to 
laboratory tests, and the physicians forwarded the questionnaires to the patients, who 
completed a questionnaire and returned it with their written consent. For children, parents or 
guardians filled in the questionnaire, and gave their informed consent. 
 
As 206 patients in Studies I and II returned the questionnaire, the response rate was 57% 
(Figure 3). Further, 14 patients were excluded because the isolates were lacking or because 
they had a co-infection. A total of 192 patients with C. jejuni/ C. coli enteritis were included 
in Study I, and 166 patients with C. jejuni enteritis in Study II. 
 
 
Figure 3 Flow chart of patients included in Campylobacter enteritis Studies I and II. 
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Questionnaires 
The questionnaires contained detailed questions about occurrence, timing, and time-period of 
symptoms, background information such as underlying diseases or medical conditions, 
foreign travel, and medication. In addition, they asked for data on treatment and post-
infectious complications, with emphasis on timing and length of antimicrobial therapy. 
 
Occurrence of the following symptoms was specifically inquired; diarrhea, watery stools, 
bloody stools, slimy stools, headache, abdominal pain, fever, chills, cramps, nausea, 
vomiting, myalgia, and weight-loss. The patients filled in the length of time with diarrhea, 
headache, abdominal pain, fever, nausea, vomiting, myalgia, and other self-reported 
symptoms, and whether they had prodromal symptoms, and their timing. 
 
Travel information covered any foreign or domestic travel within two weeks prior to onset of 
symptoms. The patient’s own opinion regarding the source of infection, as well as suspicion 
of horizontal disease transmission, was included. The patients reported the length and timing 
of any hospital treatment for Campylobacter infection. 
 
The patients stated whether they had used any medication in the month prior to onset of 
illness, and described their use of antibiotics, cortisone, and antacids or any antibiotic 
treatment for Campylobacter infection,  the  names  of  the  drugs,  and  length  and  timing  of  
antimicrobial therapy. 
 
As to underlying diseases, these specifically were diabetes, gastric, intestinal, cardiovascular, 
and rheumatic diseases, as well as diseases increasing susceptibility to infections, and any 
episodes of Campylobacter infection. 
 
Occurrence of post-infectious symptoms was included, such as arthralgia, tendinitis, eye 
symptoms indicating conjunctivitis/iritis, and skin blisters, nodules and rashes, angina 
pectoris, arrhythmias, prolonged intestinal symptoms, as well as neurological symptoms. The 
patients stated whether they had been treated at a hospital or had received antimicrobial 
therapy for post-infectious symptoms. 
 
Finally came total length of illness and the patients’ own descriptions of their convalescence. 
4.1.2 Campylobacter bacteremia patients (III, IV) 
The Campylobacter bacteremia study was a nationwide retrospective study, essentially 
covering all C. jejuni and C. coli bacteremia cases diagnosed in Finland within the 10-year 
period 1998-2007. The patients were identified from the National Infectious Diseases 
Register (NIDR), as well as from the blood culture isolates received from microbiological 
laboratories throughout the country. In total, 119 Campylobacter bacteremia cases were 
reported to the NIDR in 1998-2007, and 95 bacterial isolates were obtained from 
microbiological laboratories. However, as comparison of patient information and 
characteristics of Campylobacter bacteremia isolates was of special interest, only those cases 
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for which all information and bacterial isolates were available were included. A flow chart 
for the selection and exclusion of patients in Studies III and IV is in Figure 4. 
 
 
Figure 4 Flow chart of patients included in the Campylobacter bacteremia Studies III and IV. 
Patient information 
The hospital treatment records of patients are routinely stored in hospital archives. From such 
archives throughout Finland, detailed information was reviewed regarding the course of 
disease,  symptoms,  and  treatment.  The  time-range  for  follow-up  of  patient  data  was  from  
admission until one year after the Campylobacter-positive blood culture. Information 
regarding background, symptoms, laboratory results, course of disease, treatment, outcome, 
and follow-up, when available, was documented for all patients. 
 
Relevant background information included documented antibiotic use before the bacteremic 
episode, foreign travel within two weeks before the onset of symptoms, initial symptoms, and 
referral diagnoses. 
 
Relevant information regarding all available patient symptoms from hospital treatment 
records was systematically documented as follows: occurrence and length of diarrhea and 
fever, and occurrence of bloody stools, slimy stools, watery stools, abdominal cramps, 
abdominal pain, vomiting, myalgia, and arthralgia. Fever was defined as an axillary or rectal 
temperature of >37.9°C documented at least once during the hospital stay; the highest 
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measured temperature was also noted, as were blood pressure levels (at admission, and 
lowest), and tachycardia at admission. 
 
All relevant laboratory test results were documented, and levels at admission to hospital and 
discharge from hospital, as well as lowest and highest levels. Laboratory test results included 
hemoglobin, leukocyte, and platelet count, alcalic phosphatase (AFOS), amylase, bilirubin, 
Campylobacter antibodies, C-reactive protein (CRP), calcium, creatinine, potassium, sodium, 
and transaminases ALAT and ASAT, human leukocyte antigen B27 (HLA-27), as well as 
stool cultures and urine findings. 
 
Detailed hospital treatment information specifically involved length of hospital treatment, 
need for intensive care unit (ICU) treatment, length and timing of antimicrobial therapies, and 
radiological examinations such as computer tomography (CT) scan, echocardiography, 
magnetic resonance (MR) imaging, and thorax radiography. 
 
Data regarding underlying diseases were analyzed and scored according to the Charlson 
index (Table 5) (Charlson et al., 1987). The Charlson index score is cumulative: a Charlson 
index score ?1 indicates that the underlying disease is significant, and ?2 that the underlying 
disease is severe. 
 
Table 5. Scoring of underlying diseases according to the Charlson weighted index of comorbidity 
(adapted data from Charlson et al., 1987). 
 
Condition Weight 
   
Cerebrovascular disease 1  
Chronic pulmonary disease 1  
Congestive heart failure 1  
Connective tissue disease 1  
Dementia 1  
Diabetes 1  
Mild liver disease 1  
Myocardial infarction 1  
Peripheral vascular disease 1  
Ulcer disease 1  
Any tumor 2  
Hemiplegia 2  
Leukemia 2  
Lymphoma 2  
Moderate or severe renal disease 2  
Moderate or severe liver disease 3  
Metastatic cancer 6  
AIDS 6  
 
Information regarding antimicrobial treatment after hospitalization, post-infectious 
complications, and possible relapse or re-admission to hospital was noted, and records of 
hospital visits were reviewed. Inflammatory, neurological, or rheumatic symptoms, indicating  
arthritis, iritis, IBS, paralysis, or tendinitis, as well as possible surgical procedures, were 
noted from the next year following the bacteremic episode. Duration of sick-leave was 
documented. Any results from colonoscopy or gastroscopy were included. Mortality data 
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came from Statistics Finland, from the treatment period for Campylobacter bacteremia and 
the following year. 
4.2 Bacterial isolates 
4.2.1 Species identification 
Determination of Campylobacter enteritis isolates to species level was based on a hippurate 
hydrolysis test; positive isolates were classified as C. jejuni and negative isolates as C. coli (I, 
II). Furthermore, characteristic PFGE patterns for a subgroup of the isolates confirmed typing 
to species level. In the Campylobacter bacteremia study, isolates were genotyped by species-
specific PCR analyses for C. jejuni and C. coli (III). For the initial analyses, primers were 
designed to target the mapA gene in the C. jejuni genome and the ceuE gene in the C. coli 
genome, with findings verified by additional analyses targeting hippuricase in C. jejuni and 
aspartokinase in C. coli (III). The reference strains C. jejuni NCTC 11168, C. jejuni 811176, 
and C. coli LMG6440 served as positive controls; negative controls included one with no 
added template DNA for all bacteremia isolates, as well as the C. coli reference strain for the 
C. jejuni isolates and the C. jejuni reference strains for the C. coli isolates (III). 
4.2.2 Genotyping 
To determine whether the C. jejuni enteritis isolates were essentially clonal or diverse, all 
domestic isolates and all those isolates presumably of foreign origin from July 2006 were 
analyzed  by  PFGE  (II).  The  Campylobacter bacteremia isolates were genotyped by MLST 
(IV). 
 
The  PFGE  was  performed  with  DNA  from  the  C. jejuni isolates that were harvested from 
Brucella  blood  agar  after  two  days’  growth.  Shortly,  after  preparation  of  the  DNA  and  
digestion with KpnI, DNA plugs were loaded into sample wells of the agarose gel, and 
separated by electrophoresis with ramped pulses (Hänninen et al., 1998). Differences in at 
least one band indicated that the PFGE profiles differed. 
 
MLST was performed according to techniques described in detail (Dingle et al., 2001; 
Kärenlampi et al., 2007; de Haan et al., 2010). In short, DNA was isolated with the Wizard 
genomic DNA purification kit (Promega, Germany), to be used for PCR. PCR conditions and 
annealing temperature were chosen as earlier described (Korczak et al., 2009; de Haan et al., 
2010), and the PCR products were purified on Multiscreen PCR plates (Millipore, Billerica, 
MA, USA). Sequencing was performed by the BigDye terminator version 3.1 ready reaction 
cycle  sequencing  kit  (Applied  Biosystems,  Foster  City,  CA,  USA)  at  the  Institute  of  
Biotechnology, Helsinki, and the assembly and editing of the sequence data were performed 
with BioNumerics version 5.1 software (Applied Maths, Kortrijk, Belgium). 
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4.2.3 Antimicrobial susceptibility 
Antimicrobial susceptibility of stool culture isolates was first tested for ciprofloxacin (I) and 
then also for erythromycin (II) and doxycycline (II). In addition to these three antimicrobial 
agents, blood culture isolates were also evaluated for susceptibility to gentamicin, 
meropenem, clindamycin, and metronidazole (III). The MIC values of ciprofloxacin (Bayer 
Health Care AG, Leverkusen, Germany), erythromycin (Amdipharm Ltd, Dublin, Ireland), 
doxycycline (Orion Pharma, Espoo, Finland), clindamycin (Sigma-Aldrich, St. Louis, MO, 
USA), metronidazole (B. Braun Melsungen AG, Melsungen, Germany), gentamicin (Sigma-
Aldrich) and meropenem (Sandoz AG, Basel, Switzerland) were determined by an agar 
dilution method according to CLSI recommendations (CLSI, 2005). Mueller-Hinton agar 
(Oxoid, Basingstoke, UK) plates supplemented with defibrinated sheep blood (5%) and 
containing antimicrobial agent were prepared within 24 hours of use. The concentrations of 
the antimicrobials were as follows: ciprofloxacin 0.008–128 mg/L, erythromycin 0.125–1024 
mg/L, doxycycline 0.032–128 mg/L, gentamicin 0.016–32 mg/L, metronidazole 0.064–256 
mg/L, clindamycin 0.016–32 mg/L, and meropenem 0.001–32 mg/L. Direct colony 
suspension was prepared from overnight growth on blood agar plates by suspending the 
culture in sterile distilled water in order to obtain a turbidity of a 0.5 McFarland standard. 
 
Approximately 104 colony-forming units (CFU) were applied per spot with a multipoint 
inoculator. Quality-control strains included C. jejuni American Type Culture Collection 
(ATCC) 33560, Staphylococcus aureus ATCC 29213 (for clindamycin), and Helicobacter 
pylori ATCC 43504 (for metronidazole). The inoculated agar plates were incubated in a 
microaerobic atmosphere (BBL CampyPak Plus, Becton Dickinson CO., Sparks, MD, USA) 
at 36°C for 48 h. The MIC was the lowest concentration of the antimicrobial agent 
completely inhibiting visible bacterial growth. Antimicrobial susceptibility of the isolates for 
ciprofloxacin, doxycycline, and erythromycin were interpreted according to the CLSI 
guidelines, whereas for clindamycin, gentamicin, and meropenem, breakpoints came from the 
National Antimicrobial Resistance Monitoring System (NARMS), and for metronidazole 
breakpoints suggested by Hariharan et al. were used (Table 6). 
 
Table 6. Breakpoints for ciprofloxacin, clindamycin, doxycycline, erythromycin, gentamicin, 
meropenem, and metronidazole. 
 
Antimicrobial agent Susceptible Intermediate Resistant Reference 
ciprofloxacin ?1 mg/L 2 mg/L ?4 mg/L CLSI 
clindamycin ?2 mg/L 4 mg/L ?8 mg/L NARMS 
doxycycline ?2 mg/L 4 mg/L ?8 mg/L CLSI 
erythromycin ?8 mg/L 16 mg/L ?32 mg/L CLSI 
gentamicin ?2 mg/L 4 mg/L ?8 mg/L NARMS 
meropenem ?4 mg/L 8 mg/L ?16 mg/L NARMS 
metronidazole ?4 mg/L 8 mg/L ?16 mg/L Hariharan et al., 2009 
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4.2.4 Virulence factors 
C. jejuni enteritis isolates found to be ggt-positive by comparative genomics were further 
tested for production of GGT by a qualitative detection method (Shibayama et al., 2003).  To 
study the presence of other putative virulence factors, DNA was extracted from the C. jejuni 
enteritis isolates and tested for the presence of the genes ceuE, cgtB, ciaB, cj0486, pldA, 
virB11, and wlaN, as well as the cdtABC operon, with primers selected for detecting each of 
these genes (Table 7a). 
 
To describe the virulence factor profiles of the C. jejuni bacteremia isolates, we measured 
qualitative production of GGT as described for Helicobacter pylori (Shibayama et al., 2003), 
and presence of the genes ceuE, ciaB, cj0486, and virB11, by the same method as described 
above  for  the  enteritis  isolates.  For  screening  for  LOS  locus  classes,  the  presence  of  open  
reading frame (ORF) orf12 (waaV) served as verification for successful DNA extraction from 
all isolates. A summary of the primers used for the detection of the open reading frames 
orf7ab (sialyltransferase cstII), orf6ab1 (galactosyltransferase cgtB-1), orf6ab2 
(galactosyltransferase cgtB-2), and orf5bII (cgtA2) used for identification of sialylated LOS 
locus classes A and B, detection of orf6c (galactosyltransferase Cj1139c) and orf7c 
(sialyltransferase cstIII)  in  strains  of  sialylated  LOS  locus  class  C,  and  detection  of  orf26e  
and  orf27e  for  identification  of  nonsialylated  LOS locus  classes  E,  H,  O,  and  P,  as  well  as  
orf12 are summarized in Table 7b. 
 
Table 7a. Primers in Studies II and IV. 
   
Virulence factor gene Primer 5’-3’ Primer sequences 
   
cdtABC 1 CTTTATGCATGTTCTTCTAAATTT 
2 GTTAAAGGTGGGGTTATAATCATT 
   
ceuE 1 GATAAAGTCGTTGGCGTTCC 
2 GCGAGATTGGAGGACCAAAGG 
   
ciaB 1 CAGAAGGAGAAATTTGTGAGC 
2 ATATCCCATTCTAATGCCACC 
   
cj0486 1 GATAGAGCATTAAATTGGGATG 
2 CCTATAAAGCCATACCAAGCC 
   
cgtB 1 TTAAGAGCAAGATATGAAGGTG 
2 GCACATAGAGAACGCTACAA 
   
pldA 1 AAGCTTATGCGTTTTT 
2 TATAAGGCTTTCTCCA 
   
virB11 1 TCTTGTGAGTTGCCTTACCCCTTTT 
2 CCTGCGTGTCCTGTGTTATTTACCC 
   
wlaN 1 TTAAGAGCAAGATATGAAGGTG 
2 TGCTGGGTATACAAAGGTTGTG 
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Table 7b. Primers for LOS classification. 
    
ORF (gene) LOS locus class Primer 5’-3’    Primer sequences 
    
12 (waaV) all 1 GCCACAACTTTCTATCATAATCCCGC 
2 CGCCGTAACTCAAACGCTCATCTATT 
    
6ab1 (cgtB-1) A1*, B1* 1 CAAGGGCAATAGAAAGCTGTATCA 
2 ACAAGCACTTCATTCTTAGTATTACAAAT 
    
6ab2 (cgtB-2) A2*, B2* 1 TCATCTTGCCAACTTATAATGTGGA 
2 TCTAGCGATATTAAACCAACAGCCT 
    
7ab (cstII) A1*, A2*, B1*, 
B2* 
1 ACTACACTTTAAAACATTTAATCCAAAATCA 
2 CCATAAGCCTCACTAGAAGGTATGAGTATA 
    
5bII (cgtA2) B1*, B2* 1 CTGTGATGATGGGAGTGAAGAGC 
2 GGTAATCGTTTCGGCGGTATT 
    
6c (Cj1139c) C* 1 GTAGTAGATGATTGTGGTAATGATAAA 
2 ATAGAATTGCTATTTACATGCTGG 
    
7c (cstIII) C* 1 TTGAAGATAGATATTTTGTGGGTAAA 
2 CTTTAAGTAGTGTTTTATGTCACTTGG 
    
26e E, O 1 ATATTGCCGTTAATTCATTACAGTT 
2 TTTGAGCGATAATTTTAAATCCATC 
    
27e E,H, O, P 1 GTAGATGATTGTTCAAATGATAATAGCACA 
 2 GTTTTCAGATTCTAAGGCCATTATTCC 
*Sialylated LOS locus classes. 
 
Primers for orf18df (5’-GCAGCAAGAAATAATGGTGTTAAAC-3’, and 5’-
AAATAATCATCCAAACATTCCTGAA-3’) show bands for the nonsialylated LOS locus 
classes  D,  F,  I,  J,  K,  N,  S,  or  Q  and  were  used  to  attribute  isolates  non-typable  using  the  
primers above. 
4.2.5 Serum resistance (IV) 
A serum-sensitivity assay of the C. jejuni bacteremia isolates was performed as described 
(Blaser et al., 1985; Guerry et al., 2000). The same pool of normal human serum (NHS) from 
the blood samples of ten healthy blood donors served for all experiments. Heat-inactivated 
NHS (HINHS) was prepared by placing the test tubes in a waterbath of 56?C for 45 min. 
Bacterial cells from the 73 C. jejuni isolates were cultured in Brucella broth (Becton 
Dickinson) overnight, optic density at 405 nm was measured, and then bacterial density was 
adjusted to 5 x 104 CFU/mL by serial dilution. Next, 100 µl of the diluted bacterial 
suspension was added to 350 µl of PBS and 50 µl of NHS or HINHS, followed by incubation 
for 120 min at 37?C, after which 100 µl aliquots were plated out on blood agar plates 
(Columbia agar II (Neogen, Lansing, MI, USA) containing 8% vol/vol of defibrinized horse 
blood), and the plates were incubated under microaerobic conditions for 24 h at 42?C. The 
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number of colonies recovered from the NHS plates, divided by the number recovered from 
HINHS plates, and multiplied by 100, gave the percentage (%) of bacterial survival. The final 
analysis used mean values of two or three separate experiments. C. jejuni NCTC 11168 and a 
C. fetus blood isolate received while collecting the C. jejuni and C. coli blood isolates, served 
as control organisms. The C. fetus isolate was incubated at 37°C. 
4.3 Statistical analyses 
The statistical analyses were performed with Graphpad Prism version 4.03 (Graphpad 
Software, San Diego, CA, USA), SPSS version 15.0 (SPSS, Chicago, IL, USA), and PASW 18 
(SPSS Inc). Fisher’s exact test and the ?2-test  and  Mantel-Haenszel  test  were  used  for  
comparison of categorical variables. The Mann-Whitney test was used for comparison of 
continuous variables. Multivariate analyses were performed with stepwise binary logistic 
regression models. All tests were two-sided, and a p-value <0.05 was considered statistically 
significant. 
4.4 Ethical considerations 
The studies were approved by the Ethics Committee of the Hospital District of Helsinki and 
Uusimaa (Studies I and II). Written informed consent came from all patients– or their parents 
or guardians– included in Studies I and II. Studies III and IV were approved by the Finnish 
Ministry of Social Affairs and Health.  
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5. Results 
5.1 Patient data 
5.1.1 Overview of patient characteristics 
Included in the studies were 192 patients with C. jejuni or C. coli enteritis (I), 166 C. jejuni 
patients of whom were also included in Study II, and 76 patients with C. jejuni or C. coli 
bacteremia (III), 73 C. jejuni patients of whom were also included in Study IV. 
 
A summary of patient characteristics, including a comparison between patients with either C. 
jejuni/ C. coli enteritis or bacteremia, is presented in Table 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
Table 8. Background, travel, and treatment data for patients in Studies I and III. 
Patient characteristics Enteritis study, 
2006 (I) N=192 
Bacteremia study, 
1998-2007 (III) N=76 
Age, years, median 39 46 
Gender, proportion of male patients 42% 74% 
   
Travel-associated infection (%) 148/192 (77) 16/76 (21) 
Travel destination:   
Baltic states/ Poland 11 2 
Bulgaria 21  
Central Europe/ UK/ Ireland 20 3 
Cyprus/ Greece/ Italy 12  
India/ Nepal 14  
Northern Africa/ Middle East 8 1 
Spain/ Portugal 25  
Sub-Saharan Africa 3  
Sweden/ Denmark 2 2 
Thailand/ Cambodia/ Malesia 14 3 
Turkey 11 2 
Other 5 1 
Unknown 3 2 
Underlying disease, any (%) 43/187 (23) 48/76 (63) 
alcohol abuse/ liver disease 0 6 
chronic pulmonary disease 0 5 
diabetes 3 4 
diverticulosis/ celiac disease 4 2 
dyspepsia/ gastritis/ GER/ peptic ulcer 12 5 
malignant disease 2 4 
HIV-infection 2 1 
hypertension 10 14 
rheumatoid arthritis/ fibromyalgia 5 1 
Hospitalized for ? 2 days (%) 31/190 (16) 67/75 (89) 
Received antimicrobial treatment (%) 140/191 (73) 73/76 (96) 
GER= gastroesophageal reflux 
 
The  median  age  of  the  enteritis  patients  in  Study  I  did  not  differ  between  the  26  patients  
infected by C. coli (38 years), and the 166 patients infected by C. jejuni (39 years), and the 
proportion of presumably imported infections was also similar between these two patient 
groups (85% and 76%). 
 
Younger age-groups were slightly under-represented in Study I (Figure 5). 
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Figure 5 Age distribution of patients in Study I, for all Campylobacter-positive patients during 
the 6-month study period, and those included in the study. 
 
A patient was classified as having an underlying disease if any medical condition or disease 
was either self-reported by the patient (I), or had been noted in the hospital records (III). In 
the bacteremia study, significant underlying diseases were further identified by classification 
of the illnesses according to the Charlson index score (Table 5), and the patients were divided 
into three groups; Charlson index scores 0, 1, and ?2. Although the majority of the 
bacteremic patients had some underlying disease, as shown in Table 8, the proportion of 
patients who had significant underlying diseases was clearly lower; only 30% were grouped 
with Charlson index score ?1. 
 
Enteritis patients had underlying diseases less frequently than did bacteremic patients (Table 
8), and although the data were self-reported by the patients, the more severe diseases seemed 
less frequent among these patients as well, compared to the bacteremic patients in Study III. 
Further, alcohol-related diseases and chronic pulmonary diseases seemed either under-
represented or under-reported among the patients with enteritis, or over-represented among 
the bacteremia patients (Table 8). 
 
The  median  age  of  the  patients  with  C. jejuni/ C. coli bacteremia was 46 years, and the 
median  age  of  patients  with  Charlson  index  scores  0,  1,  and  ?2  was  41,  54,  and  57  years.  
Patients without significant underlying diseases were younger than those with a Charlson 
index score of either 1 (p=0.002), or ?2 (p=0.004). 
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5.1.2 Foreign travel before onset of illness 
An infection was regarded as imported if the patient had traveled abroad within two weeks 
prior  to  the  onset  of  symptoms  (I,  III).  The  majority  of  the  patients  in  the  Campylobacter 
enteritis study (I) had presumably been infected abroad (Table 8). When comparing 
characteristics of domestically infected patients and those patients with presumably imported 
infection in Study I, we found that the age distribution differed, but no significant differences 
in the distribution of any underlying diseases or gender were detectable (Table 9). 
 
Table 9. Distribution of age, any underlying diseases, and gender among 44 patients with domestic 
and 148 patients with imported C. jejuni/ C. coli enteritis (I). 
Patient characteristic Domestic infection Imported infection p-value 
Age, years, median 46 37 0.03* 
Any underlying disease, no. of patients (%) 13 (30%) 30 (21%) 0.2 
Male gender, no. of patients (%) 21 (48%) 60 (41%) 0.4 
 
In contrast to the finding that foreign travel was common among the patients with C. jejuni or 
C. coli enteritis, only 21% of the C. jejuni or C. coli bacteremia patients were known to have 
traveled abroad before onset of illness (Table 8).  Further,  some of the most common travel 
destinations among the patients with enteritis,  for example Bulgaria,  Spain,  and India,  were 
not included for patients with bacteremia. 
5.1.3 Clinical signs and symptoms 
Information  regarding  clinical  symptoms  and  the  course  of  disease  came  from  either  
questionnaires filled in personally by the patients with C. jejuni or C. coli enteritis (I), or 
collected from the medical records at the hospitals where the C. jejuni or C. coli bacteremia 
episodes were diagnosed (III). The prevalences are summarized in Table 10. 
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Table 10. Prevalence of specific clinical signs and symptoms, either reported directly by patients with 
C. jejuni or C. coli enteritis, or noted in the medical records of patients with C. jejuni or C. coli 
bacteremia. 
Clinical symptom or sign C. jejuni / C. coli enteritis 
patients 
C. jejuni / C. coli bacteremia 
patients 
Reported 
no. of patients (%) 
Answer 
rate (%) 
Reported 
no. of patients (%) 
Mention rate 
(%) 
Abdominal cramps   15/31 (48) 41 
Abdominal pain 158/182 (87) 95 35/54 (65) 71 
Diarrhea 191/192 (99) 100 60/64 (94) 84 
duration ? 5 days 74/192 (39)  15/64 (23)  
duration >5 days 112/192 (58)  22/64 (34)  
duration ? 10 days 47/192 (24)    
duration uncertain 5/192 (3)  23/64 (36)  
Bloody stools 24/133 (18) 69 7/24 (29) 32 
Fever 160/183 (87) 95 64/75 (85) 99 
Myalgia 73/174 (42) 91 11/15 (73) 20 
Vomiting 48/179 (27) 93 13/43 (30) 57 
 
Information on the occurrence and length of specific clinical symptoms seemed to be more 
detailed in the questionnaires returned by the patients with enteritis (I) than in the data from 
the medical records of the bacteremia episodes (III), as shown in Table 10. 
 
Because of the low mention rate of many symptoms in the medical records, the actual 
proportion of all patients with bacteremia with any specific symptom is lower than the 
estimated prevalence, calculated for those patients for whom the presence or absence of the 
symptom was clearly stated in the medical records. For example, 79% (60/76) of the 
bacteremia patients had diarrhea, compared to 94% of those for whom this information was 
available, and similarly 9% (7/76) had bloody stools, compared to 29% of those clearly 
reported (Table 10). 
 
When the patients with enteritis were divided into three major age-groups (< 30 years, 30-59 
years, 60-89 years), to exclude age as a confounding factor, two evident age-related 
associations emerged. First, among those aged 0 to 29, bloody stools were associated with 
diarrhea lasting ? 10 days (p=0.02). Second, among the patients aged 30 to 59, bloody stools 
were associated with domestic infection (p=0.01). None of the patients aged 60 to 89 reported 
bloody stools. 
 
In addition to the apparent differences in symptoms between patients with C. jejuni or C. coli 
enteritis and bacteremia, some variance appeared in the symptoms and findings between 
patients of different Charlson index scores in Study III. Patients with significant underlying 
diseases had less frequently fevers (>37.9°C), and generally lower levels of initial 
hemoglobin and C-reactive protein (CRP) levels, than did patients without significant 
underlying diseases (Table 11). 
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Table 11. The most common symptoms and findings in patients with C. jejuni or C. coli bacteremia, 
among patients with Charlson index scores 0, and ?1. 
Symptom/finding Charlson index score 0 
(N=53) 
Charlson index score ?1 
(N=23) 
p-value 
Diarrhea, patients 43 17 0.5 
Fever, patients 48 16 0.02* 
Hemoglobin, initial, median, g/L 144 128 0.01* 
Leukocyte count, initial, median, 
cells x 109 
9.3 8.0 0.2 
CRP, initial, median, mg/L 131 93 0.03* 
CRP, peak, median, mg/L 152 151 0.5 
Note. CRP= C-reactive protein. 
5.1.4 Hospital treatment 
Referral to diagnostic stool culture tests and initiation of treatment of a patient with C. jejuni 
or C. coli enteritis was usually by a physician at a health care center, whereas all blood 
cultures were made at a hospital. Consequently, the majority of patients with C. jejuni or C. 
coli bacteremia were primarily examined at a hospital emergency clinic, but relatively fewer 
patients with C. jejuni or C. coli enteritis were referred to a hospital. For analyses of factors 
which could lead to need for hospital treatment, patients treated at a hospital for at least two 
days were considered as hospitalized patients (I).  The proportion of patients treated at a 
hospital for ?2 days was 16% among the patients with C. jejuni or C. coli enteritis, and 89% 
among the patients with C. jejuni or C. coli bacteremia (Table 8). 
5.1.5 Antimicrobial treatment 
Information regarding the antimicrobial treatment came from questionnaires sent to the 
enteritis patients, and data on whether antimicrobials had been administered, which 
antimicrobial drugs were used, and the timing of antimicrobial treatment came from hospital 
records of patients treated for bacteremia. The majority of patients received antimicrobial 
treatment, 73% of the patients with C. jejuni or C. coli enteritis (I), and 96% of the patients 
with C. jejuni or C. coli bacteremia (III) had received at least one antimicrobial agent (Table 
8). The proportion of patients receiving antimicrobial therapy with agents from more than one 
group of antimicrobials was 19% among the enteritis patients, and 71% among those with 
bacteremia.  The  distributions  of  different  antimicrobial  agents  used  in  the  treatment  of  the  
patients included in Studies I and III are shown in Table 12. 
 
 
 
 
 
 
 
 
 
48 
 
Table 12. Antimicrobial agents in treatment of patients in Studies I and III. 
Antimicrobial agent Enteritis study (I) 
N=192 
Bacteremia study (III) N=76 
At hospital After hospitalization 
Fluoroquinolone 68 44 46 
Ciprofloxacin 65 38 43 
Levofloxacin  5 2 
Norfloxacin 3   
Ofloxacin  1 1 
    
Macrolide 76 15 13 
Azithromycin 5 3 0 
Clarithromycin 0 2 1 
Erythromycin 33 5 5 
Roxithromycin 38 5 7 
    
Aminoglycoside 1 6 0 
Amoxicillin-clavulanic acid 0 0 1 
Carbapenem 0 1 0 
Cephalosporin 8 38 7 
Clindamycin 0 3 0 
Doxycycline 3 1 1 
Metronidazole 11 19 9 
Penicillin 0 1 0 
Vancomycin 0 1 0 
 
5.1.6 Outcome of illness 
Campylobacter enteritis patients (I) 
The proportion of enteritis patients reporting post-infectious musculoskeletal symptoms was 
approximately 24%, but because these data came from the patients’ questionnaires, no other 
information regarding follow-up or outcome was available. 
 
Bloody  stools,  diarrhea  lasting  ?10  days,  and  hospitalization  were  chosen  as  indicators  for  
more severe disease, and respectively 18%, 24%, and 16% of the patients had reported these 
in the questionnaires (Tables 8 & 10). 
 
No known fatalities occurred among patients in Study I. 
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Campylobacter bacteremia patients (III) 
Outcome of Campylobacter bacteremia was measured by length of hospital treatment, by 30-
day and one-year mortality records, and by occurrence of severe post-infectious 
complications documented in the hospital treatment records. 
 
Length of hospitalization was compared for patients with differing severity of underlying 
diseases. Patients without significant underlying diseases (Charlson index score 0) had a 
median duration of hospitalization of 3.5 days; the Mann-Whitney test revealed a significant 
difference in median duration of hospitalization of the patients with a Charlson index score of 
1 (6 days; p=0.04), as well as for those patients whose Charlson index score was ?2 (7.5 
days, p=0.002). 
 
Data regarding length of hospitalization for bacteremia patients, who had received either 
appropriate empirical antimicrobial treatment or inappropriate, delayed, or no antimicrobial 
treatment, are shown in Table 13. 
 
Table 13. Median duration of hospitalization of 75 patients with C. jejuni  / C. coli bacteremia, by 
appropriateness of antimicrobial therapy. 
 All 
patients 
(N=75)a 
Appropriate antimicrobial therapy Inappropriate
or no 
antimicrobial 
therapy 
(N=25) 
p 
All 
(N=50) 
Empirical 
(N=30) 
Delayed 
(N=20) 
Hospitalization (median, 
days) 
4 5 4 6 3  
       
Comparison of patients 
receiving: 
      
       
Appropriate vs. 
inappropriate or no 
antimicrobial therapy 
 5   3 0.01* 
Appropriate empirical vs. 
delayed appropriate 
antimicrobial therapy 
  4 6  0.03* 
Appropriate empirical vs. 
delayed appropriate, 
inappropriate, or no 
antimicrobial therapy 
(N=45, median duration 4 
days) 
  4 4 NS 
aFor one patient this information was unavailable. 
 
Two deaths occurred within 30 days after the Campylobacter-positive blood culture, and thus 
the mortality attributable to bacteremia was 3%. In addition, 6 patients died within one year 
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of the bacteremic episode, but these deaths were either attributed to severe underlying 
disease, old age, or trauma. 
 
For the patients with bacteremia, clinical follow-up data were reviewed from the hospital 
archives of the same hospital where the blood culture had been performed; the time period for 
follow-up was one year, starting from the date of the blood culture. Although some of the 
patients had documented later visits to the hospital, hospital records revealed only a limited 
amount of information regarding the outcome of infection and possible complications. 
 
One  patient  was  diagnosed  with  Guillain-Barré  syndrome,  and  after  hospital  treatment  was  
referred to a neurological rehabilitation clinic. 
 
Another patient was diagnosed with C. jejuni bacteremia and concurrent cervical 
spondylodiscitis. Microbiological verification from the drainage aspirate was lacking, but the 
patient was already receiving appropriate macrolide therapy at the time of the surgical 
procedure. 
 
Appendectomy was performed on two patients while they were hospitalized, and two other 
patients were cholecystectomized during the one-year follow-up. Further, two patients were 
diagnosed with an inflammatory bowel disease within the follow-up period, as colonoscopy 
and biopsies revealed suspected findings of Crohn’s disease in one patient, and lymphocytic 
colitis in another. 
5.2 Bacterial isolates 
5.2.1 Genotype distribution 
PFGE analysis of fecal isolates (II) 
All domestic fecal Campylobacter isolates from July through December 2006 were analyzed 
with  PFGE,  revealing  a  high  diversity  of  PFGE  profiles,  as  33  different  PFGE  types  were  
detected among the 40 domestic C. jejuni isolates included in Study II. Three isolates had an 
identical PFGE, and five other PFGE types had two isolates each. 
 
Grouping domestic isolates further into crude clusters with ?70% similarity, revealed two 
larger crude clusters including 7 isolates each. 
 
Of the imported 35 Campylobacter isolates from July 2006, all C. jejuni isolates were of 
different PFGE types. 
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MLST analysis of the blood isolates (IV) 
All C. jejuni and C. coli blood isolates were typed with MLST; the 73 C. jejuni isolates were 
of 11 different clonal complexes (CC), and all three C. coli isolates were of the ST-828 CC 
(Table 14). 
 
Table 14. MLST clonal complexes of 73 C. jejuni and three C. coli blood isolates. 
CC N Species Sequence types (N) 
ST-677 35 C. jejuni 677 (27), 794 (8) 
ST-45 12 C. jejuni 11 (4), 45 (3), 137 (2), 230 (2), 5201 (1) 
ST-21 10 C. jejuni 50 (5), 883 (2), 1948 (1), 5670 (1), uncertain* (1) 
ST-48 2 C. jejuni 38 (1), 48 (1) 
ST-464 2 C. jejuni 464 (1), 3140 (1) 
ST-52 1 C. jejuni 52 (1) 
ST-354 1 C. jejuni 3155 (1) 
ST-443 1 C. jejuni new ST (1) 
ST-460 1 C. jejuni 606 (1) 
ST-508 1 C. jejuni 508 (1) 
ST-1332 1 C. jejuni 1332 (1) 
ST-828 3 C. coli 825 (1), 872 (1), new ST (1) 
Unassigned 5 C. jejuni 468 (1), 1080 (1), 1972 (1), 5673 (1), 5674 (1) 
Mixed 1 C. jejuni  
*Sequence data obtained for 5 loci. 
 
There was an evident over-representation of ST-677 CC isolates among the C. jejuni blood 
isolates; the comparatively common ST-45 CC and ST-21 CC were also found more 
frequently than were other CCs, and of all C. jejuni blood isolates, 78% were of one of these 
three MLST CCs (Table 14). 
 
Although the majority (71%) of the bacteremia isolates were isolated from blood cultures 
taken during the months of May through April, the seasonal peak was attributed to some 
MLST CCs more closely than to others; 100% of the isolates of the ST-677 CC, 67% of the 
isolates of the ST-45 CC, and 40% of the isolates of the ST-21 CC were diagnosed during the 
summer seasonal peak, May through August (Figure 6). 
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Figure 6 Seasonal distribution of bacteremia-associated C. jejuni MLST CCs. 
5.2.2 Antimicrobial susceptibility 
Minimal Inhibitory Concentration (MIC) 
All isolates were tested with an agar dilution method to determine the MIC values for the 
antimicrobial agents most commonly used as treatment for Campylobacter infection.  We  
tested by an agar-dilution method the susceptibilities of the bacterial isolates to ciprofloxacin 
(I,III); doxycycline, and erythromycin (II,III); as well as to clindamycin, gentamicin, 
meropenem, and metronidazole (III) (Table 15). 
 
Table 15.Number of isolates resistant to different antimicrobial agents, among enteritis isolates, and 
in Study III. 
Antimicrobial agent No. of isolates resistant (%) 
Enteritis isolates N=192 Bacteremia study (III) N=76 
ciprofloxacin 97 (51%) 5 (7%) 
clindamycin n.a. 0 
doxycycline 73 (38%) 3 (4%) 
erythromycin 8 (4%) 0 
gentamicin n.a. 0 
meropenem n.a. 0 
metronidazole n.a. 12 (16%) 
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A clear difference emerged in resistance patterns between the enteritis and the bacteremia 
isolates. In both groups of isolates, antimicrobial resistance to ciprofloxacin, doxycycline, 
and erythromycin was detected almost exclusively in imported isolates. Of the isolates which 
were resistant to ciprofloxacin, all except one were of foreign origin (Figure 7). 
 
 
Figure 7 Distribution of ciprofloxacin MICs for 192 C. jejuni  / C. coli fecal isolates and 76 C. 
jejuni  / C. coli blood isolates. Data labels are shown for the imported isolates (N=164). 
Effect of ciprofloxacin resistance on disease outcome (I) 
There was a significant difference in distribution of ciprofloxacin MICs between the patients 
who reported bloody stools (67% of their isolates were highly susceptible, MIC 0.06-0.25 
mg/L, to ciprofloxacin), and those patients who reported noticing no bloody stools (p=0.04); 
a significant difference in the distribution of MICs was also evident between patients 
hospitalized ?2 days (65% of their isolates were susceptible to ciprofloxacin), and those who 
had not been hospitalized ?2 days (p=0.01).  In the light of these results, a more severe 
outcome of infection seemed to be associated with a lack of ciprofloxacin resistance in the 
Campylobacter enteritis strains. 
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5.2.3 Putative virulence factors (II, IV) 
The isolates were analyzed for the presence of the putative virulence factor genes ceuE, 
involved in iron uptake (II, IV), cgtB, involved in sialylation of LOS (II), ciaB, encoding the 
Campylobacter invasion antigen (II, IV), cj0486, encoding a putative fucose permease (II, 
IV), pldA, encoding phospholipase A (II), virB11  of  the  pVir  plasmid  (II,  IV),  and  wlaN, 
involved in sialylation of LOS (II), and the operon cdtABC, encoding the cytolethal 
distending toxin (II), as well as for the production of GGT (II, IV) (Table 16). 
 
Table 16. Prevalence of the putative virulence factor genes ceuE, cgtB, ciaB, cj0486, pldA, virB11, 
and wlaN, as well as the operon cdtABC among C. jejuni isolates in Studies II and IV. 
Study cdtABC ceuE cgtB ciaB cj0486 pldA virB11 wlaN 
II 131 
(79%) 
142 (86%) 31 
(19%) 
164 (99%) 81 (49%) 101 
(61%) 
4 (2%) 39 
(23%) 
IV n.a.* 71 (97%) n.a.* 73 (100%) 17 (23%) n.a.* 2 (3%) n.a.* 
*n.a.=not available. 
 
GGT production was detected in 25/166 (15%) of the C. jejuni enteritis isolates, and in 13/73 
(18%) of the C. jejuni blood isolates. It should be noted that the proportion of cj0486-positive 
isolates was significantly higher among the C. jejuni enteritis patients than among the C. 
jejuni bacteremia patients (Table 16; p=0.0002). 
Associations between putative virulence factors and disease among C. jejuni 
enteritis patients (II) 
Univariate analyses revealed that bloody stools reported by the patients were a clinical sign 
associated with the presence of gene cgtB (p=0.03), and the production of GGT (p=0.03). 
The absence of the gene ceuE was associated with hospitalization (p=0.03). Isolates shown to 
produce GGT were associated with ciprofloxacin susceptibility (p=0.001), and doxycycline 
susceptibility (p=0.003), while isolates positive for either ceuE or cj0486 were associated 
with resistance to ciprofloxacin (p<0.001, p=0.005, respectively), and resistance to 
doxycycline (p<0.0001, p=0.002). Those isolates which were positive for either ceuE or 
cj0486 were associated with imported infection (p<0.0001), while isolates which produced 
GGT were associated with domestic infection (p<0.0001). 
 
All results could not be analyzed by multivariate analysis, due to missing data. When those 
factors possible to test with a multivariate analysis model underwent testing, the only 
associations  remaining  significant  were  those  with  production  of  GGT,  and  the  presence  of  
genes ceuE or cj0486, compared to the origin of infection. Isolates which produced GGT 
were significantly associated with domestically acquired infection (OR 8.7, p<0.0001), and 
isolates positive for ceuE or cj0486 were significantly associated with infection of 
presumably foreign origin (OR 6.7, p<0.0001, respectively). 
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Associations between virulence factors and the C. jejuni MLST CCs of the 
bacteremia isolates (IV) 
Certain putative virulence factors were associated with certain MLST CCs. Isolates of the 
ST-45  CC  were  mostly  GGT  positive  (83%),  compared  to  only  three  other  GGT-positive  
strains (p<0.0001). The fucose permease gene cj0486 was associated with ST-21 CC isolates 
(100% of ST-21 CC cj0486 positive, vs. 14 % of all other isolates; p <0.0001). All isolates 
were ciaB positive, all isolates except two were virB11 negative, and all isolates except two 
ceuE positive (Table 16). All the 35 ST-677 CC isolates were cj0486 negative and GGT 
negative. The most important putative virulence factor associations are summarized in Figure 
8. 
 
 
 
Figure 8 Summary of the associations of some putative virulence factors with origin of infection 
among C. jejuni fecal  isolates  (II),  and  with  certain  MLST CCs  among  the  C. jejuni blood isolates 
(IV). 
Sialylated LOS (IV) 
Only 17 (23%) of the 73 C. jejuni blood culture isolates in Study IV had a gene profile 
indicating that these isolates had sialylated LOS in their outer membranes. In total, four 
isolates had LOS locus class A1, five isolates had LOS locus class B2, and eight isolates had 
LOS  locus  class  C.  C. jejuni blood isolates with sialylated LOS were associated with the 
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presence of gene cj0486 (p<0.0001), and those patients infected by a C. jejuni isolate with 
sialylated LOS had significant underlying diseases (Charlson index score ?1) more often than 
the other patients (p=0.02). However, no difference existed in the duration of hospitalization 
among those patients infected by a C. jejuni isolate with either sialylated or nonsialylated 
LOS. 
 
All isolates of the ST-677 CC, as well as the ST-45 CC, belonged to one of the nonsialylated 
LOS locus classes E, H, O or P.  CCs associated with sialylated LOS were ST-21 CC (LOS 
locus classes A1 and C), ST-48 CC (LOS locus class B2), and ST-464 CC (LOS locus class 
B2). All C. jejuni isolates with sialylated LOS locus class C were of the ST-21 CC. 
5.2.4 Serum resistance (IV) 
Between C. jejuni isolates  of  different  MLST  complexes  susceptibility  to  NHS  varied  
significantly; isolates of the ST-677 CC were significantly less susceptible to NHS than were 
all other isolates (p<0.0001), whereas the isolates of the ST-45 CC were significantly more 
susceptible to NHS than were all other isolates (p<0.0001). 
 
No significant difference emerged in susceptibility to NHS of the C. jejuni blood isolates 
with nonsialylated LOS (27% bacterial survival, median), compared to that of isolates with 
sialylated LOS (15% bacterial survival, median) (p=0.28), and the serum susceptibility of C. 
jejuni isolated from the blood of patients with or without significant underlying diseases did 
not  differ  statistically  (patients  with  Charlson  index  score  0  compared  to  all  others,  p=0.7)  
(Figure 9). 
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Figure 9 Scatter  plot  of  the  values  and  medians  of  bacterial  survival  (%),  showing  the  serum  
susceptibility pattern of C. jejuni blood isolates with sialylated or nonsialylated LOS, as well as for 
the same isolates according to the Charlson index score of the host.  
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6. Discussion 
6.1 Effect of ciprofloxacin resistance on outcome of C. jejuni or C. 
coli infection (I, III) 
No consensus exists in the literature regarding the effect of antimicrobial resistance of C. 
jejuni on the severity of symptoms or the disease outcome. Fluoroquinolone resistance may 
impair the fitness of C. jejuni and C. coli (Zeitouni & Kempf, 2011), but the opposite effect 
was earlier noted for C. jejuni (Luo et al., 2005). Some studies have proposed a link between 
ciprofloxacin resistance and more severe infections (Engberg et al., 2004; Nelson et al., 2004; 
Helms et al., 2005), while others have shown no difference in the length or severity of 
symptoms (The Campylobacter Sentinel Surveillance Scheme Collaborators, 2002; Unicomb 
et al., 2006). Further, a re-analysis of some of these conflicting data is in line with those 
studies which found no association between ciprofloxacin resistance and severe infection 
(Wassenaar et al., 2007). Our results support those of the re-analysis, as we found no 
evidence that ciprofloxacin-resistant isolates would have caused a more severe disease than 
did the isolates susceptible to ciprofloxacin. Conversely, the trend was toward those isolates 
highly susceptible to ciprofloxacin causing more severe disease, characterized by more 
frequently reported bloody stools, as well as need for hospital treatment. Moreover, the clear 
majority of blood culture isolates, which per definition caused a more severe disease, were 
susceptible to ciprofloxacin. If ciprofloxacin resistance were of importance for the disease 
outcome, then one would expect C. jejuni and C. coli bacteremia isolates resistant to 
ciprofloxacin to be more prevalent in general. 
 
The main weaknesses in our study were that the response rate was quite low, that the younger 
age groups were somewhat under-represented, and that not all patients had answered all 
questions clearly enough to be included in the analyses. However, more than half of all 
patients who had a Campylobacter-positive stool sample within the HUSLAB area during the 
six-month study period were included in the study, and all age groups were fairly well 
represented among our patients. A general problem with questionnaire-based studies is that 
patients may have difficulties remembering specific details such as the exact duration of a 
symptom or facts concerning the medication. 
 
The fact that the association between domestically acquired infection and bloody stools was 
detected only among patients aged 30 to 59 is of specific interest. This particular age group 
was well-represented and included the majority of the patients in Study I. Among the middle-
aged, the association between bloody stools and domestically acquired Campylobacter 
infection was valid, and had the answer rate been higher generally, this association may have 
been more evident in some other age-groups as well. The younger patients typically had 
bloody stools in combination with a longer duration of diarrhea, and this might be a finding 
which reflects the absence of immunity among patients in developed countries (Blaser, 1997). 
Thus, it seems logical that this association was found among the younger patients. 
Intriguingly, none of the patients aged 60 to 89 reported bloody stools. 
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These results suggest a link may exist between the absence of ciprofloxacin resistance to the 
severity of symptoms experienced by patients with C. jejuni or C. coli enteritis, or domestic 
isolates in Finland may harbor some specific virulence traits which lead to more severe 
infection.  On  the  other  hand,  it  is  possible  that  because  the  risk  for  contracting  
gastrointestinal pathogens while traveling abroad is higher than otherwise, patients may 
become infected by less virulent isolates abroad more easily, whereas partial immunity to 
those isolates encountered domestically may actually lead to more frequent detection of 
particularly virulent domestic isolates. Further, in theory, patients with imported infection 
may have felt more concerned about their infection and thus may have contacted their health 
care units more easily than those patients who had not traveled abroad prior to onset of 
illness. This may have led to an over-representation of patients with imported infection in 
Study I. If so, ciprofloxacin-resistant isolates from patients with less severe symptoms may 
be comparatively more common, especially among the younger patients; this may have 
affected the analyses. 
6.2 Virulence factor profiles of C. jejuni isolates (II, IV) 
Although several virulence factors have been proposed to be of importance for motility, 
adhesion, colonization, invasion, iron uptake, metabolism, and survival of C. jejuni in the 
human host, none of those studied have been clearly linked to a more severe outcome of 
human disease. For example, both the pVir plasmid (Bacon et al., 2000), and CiaB (Konkel et 
al., 1999), have been proposed to somehow affect the invasiveness of C. jejuni. On the other 
hand, pVir has been very uncommon in clinical isolates (Talukder et al., 2008), and while 
ciaB is commonly detected in clinical isolates (Datta et al, 2003; Talukder et al., 2008), it has 
even been negatively associated with invasiveness in vitro (Fearnley et al., 2008). Cj0486 has 
been suggested to be associated with hyperinvasiveness in vitro (Fearnley et al., 2008), but 
information  on  the  prevalence  of  cj0486  in  clinical  isolates  is  scarce.  GGT  has  so  far  been  
shown to affect the colonization potential of C. jejuni only in animal models (Hofreuter et al., 
2006; Barnes et al., 2007). 
 
The prevalence of the putative virulence factor genes ceuE, cgtB, ciaB, cj0486, pldA, virB11, 
and wlaN, and the gene cluster cdtABC, as well as the production of GGT were studied for a 
well-characterized patient material. In general, the virulence factor profiles of C. jejuni 
isolates were quite similar to those described in the literature (Datta et al, 2003; Talukder et 
al., 2008). Most evidently, virB11 was very rare, and ciaB very common among the isolates. 
However, our major findings were that the domestic and presumably imported C. jejuni fecal 
isolates differed from each other not only regarding the susceptibility to antimicrobial agents, 
but also when comparing putative virulence factor profiles. The imported isolates were 
significantly more likely to harbor the genes cj0486 and ceuE, as compared to the domestic 
isolates, which were associated with the ability to produce GGT. This suggests significant 
geographical variation in bacterial characteristics among the C. jejuni isolates which cause 
enteric disease in humans. 
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We noted some associations between certain virulence factors and clinical characteristics. 
Both production of GGT and the presence of the gene cgtB, encoding a galactosyltranferase 
which is present in some isolates with sialylated LOS, were associated in the univariate 
analyses with bloody stools. These findings could not, however, be verified in a multivariate 
model,  due  to  the  relatively  large  amount  of  missing  data  regarding  this  particular  clinical  
finding. Another association which could not be confirmed in a multivariate analysis was 
whether those isolates which lacked the ceuE gene were to some degree associated with 
hospitalization lasting at least two days. 
 
The putative virulence factor profiles of the C. jejuni blood isolates were essentially similar 
to those of the C. jejuni enteritis isolates, with the exception of the fucose permease gene 
cj0486, which was significantly more prevalent among the enteritis isolates. A possible 
explanation for this finding may be that foreign travel was comparatively uncommon among 
the bacteremia patients, and because cj0486 was associated in Study II with imported isolates 
the proportion of cj0486-positive isolates was lower among the bacteremia patients due to the 
differences in travel history between the enteritis and the bacteremia patients. However, no 
association appeared between foreign travel and cj0486 among the bacteremia patients. A 
more logical explanation would be that because the isolates of the ST-677 CC, all of which 
were cj0486 negative, were so clearly over-represented among the bacteremia isolates, the 
proportion of cj0486 obviously also differed from that of the enteritis isolates. 
6.3 Patient characteristics and treatment aspects of Campylobacter 
bacteremia patients (III) 
In studying the outcome and severity of an infection, bacteremia is an important complication 
to consider. Regarding Campylobacter bacteremia, only a few studies have presented 
epidemiological data from a wider geographical region (Skirrow et al.,  1993; Nielsen et  al.,  
2010a) or sufficiently detailed clinical information enabling analyses of the impact of 
antimicrobial therapy (Pigrau et al., 1997; Tee & Mijch, 1998; Pacanowski et al., 2008; 
Fernández-Cruz et al., 2010). Furthermore, the species of the isolates included have not been 
typed by molecular methods. A need for studies which have combined these data is therefore 
evident. 
 
The basis for the current study was a unique clinical series of patients with Campylobacter 
bacteremia from a 10-year period in Finland. Most importantly, the characteristics of the 
human hosts and of the corresponding bacterial isolates could be compared through linkage 
of the information from hospital records to the C. jejuni and C. coli isolates. Further, all 
isolates were verified to species level by PCR, which provided sufficient reliability for 
analyses of the bacterial isolates. 
 
Surprisingly, the majority of the patients had no significant underlying diseases, and all age- 
groups were represented, although the median age was lower than expected, 46 years. These 
findings differed much from several earlier studies, both with regard to the proportion of 
underlying diseases (Pigrau et al., 1997; Pacanowski et al., 2008; Nielsen et al., 2010a; 
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Fernández-Cruz et al., 2010), as well as to patient age (Pacanowski et al., 2008; Nielsen et al., 
2010a; Fernández-Cruz et al., 2010). However, the results of the largest epidemiological 
Campylobacter bacteremia study to date (Skirrow et al., 1993) are in line with ours. 
 
Unexpectedly, we found no evident effect of appropriate empirical antimicrobial treatment, 
on either the duration of hospitalization, or on the mortality attributable to the infection. This 
finding contrasts with the results of a French study which found the absence of treatment with 
appropriate antimicrobials to be associated with death (Pacanowski et al., 2008), but in line 
with a Spanish study finding no such significant association (Fernández-Cruz et al., 2010). 
 
The low mortality rate in this study (only two patients died within 30 days after the blood 
culture) was in line with that of a recent Danish study (Nielsen et al., 2010a). Two other of 
our patients developed severe complications, one patient being diagnosed with GBS, and 
another on MRI with cervical spondylodiscitis. These patients were not known to have any 
severe underlying medical conditions, and it would be tempting to suggest that some 
characteristics of the bacterial isolates enabled the development of these complications. We 
further noted that comparatively few of our patients with bacteremia had traveled abroad, 
compared to those infected by Campylobacter in Finland in general (I), and the majority of 
the bacterial isolates were susceptible to all antimicrobial agents we tested. These results 
actually support findings in Study II, that the domestic infections in Finland may in fact have 
some characteristics or traits leading in the human host to a more severe disease.   
6.4 Clonal distribution, LOS locus classification, and serum 
susceptibility among C. jejuni bacteremia isolates (IV) 
C. jejuni is known to be weakly clonal and highly diverse, as also indicated by the fact that 
over 5000 registered STs have been submitted to the PubMLST database 
(http://pubmlst.org/campylobacter). Isolates of the ST-21 CC and the ST-45 CC are generally 
common (Dingle et al., 2001; Lévesque et al., 2008), but ST-677 CC has been uncommon 
among human C. jejuni isolates. In the light of these data, it was surprising to find that among 
the C. jejuni blood isolates the ST-677 CC was so clearly over-represented. Nevertheless, in 
Finnish studies, covering essentially the same time period as ours (Kärenlampi et al., 2007; 
deHaan et al., 2010), isolates of the ST-677 CC have been relatively prevalent (Kärenlampi et 
al., 2007), although the proportion of these isolates among human C. jejuni infections has 
been diminishing (deHaan et al., 2010). 
 
Intriguingly, though, the ST-677 CC isolates also differed from the other C. jejuni isolates in 
many other aspects. All the isolates of the ST-677 CC had nonsialylated LOS as well as very 
similar profiles of putative virulence factors, and most importantly of all C. jejuni blood 
isolates the ST-677 CC isolates were significantly more serum resistant. C. jejuni blood 
isolates are not always serum resistant (Blaser et al., 1985). However, C. jejuni and C. coli 
isolates from systemic isolation sites, indicating those that spread hematogenously, have been 
serum resistant (Blaser et al., 1986). It can thus be argued that serum resistance may actually 
be necessary for development of extraintestinal Campylobacter infection foci due to 
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hematogenous spread, but not specifically for the development of C. jejuni bacteremia. In the 
latter study by Blaser et al, the majority of patients were either <1 year or ?60 years old, and 
half had some kind of medical condition probably predisposing the patient to extraintestinal 
infection. It should therefore be pointed out that the majority of patients in the current study 
were neither from the ends of the age spectrum, nor did they commonly have severe 
underlying diseases. Further, it is important to note that although serum resistance was not an 
absolute prerequisite for the C. jejuni isolates to spread into the bloodstream, the isolates of 
the ST-677 CC may have predominated due to the fact that these particular isolates were 
more serum resistant than the isolates of other MLST complexes. 
 
The  role  of  differing  outer  membrane  and  capsule  structures  with  regard  to  the  serum  
resistance of C. jejuni remains unexplained. An earlier experimental study proposed that a C. 
jejuni mutant with a nonsialylated LOS becomes more susceptible to human serum than does 
the  wild  type,  indicating  that  sialylated  LOS may play  a  role  in  the  development  of  serum 
resistance (Guerry et al., 2000). However, another group recently suggested that capsule 
expression is more likely to be of importance for complement resistance than is LOS (Keo et 
al., 2011). Only 23% of our C. jejuni blood  isolates  had  a  sialylated  LOS  locus  class,  and  
those isolates were not more serum resistant, than were all other isolates. Hence, no evident 
link between sialylated LOS and serum resistance in C. jejuni blood isolates emerged in our 
study,  and  sialylated  LOS  seems  not  to  be  necessary  for  the  development  of  C. jejuni 
bacteremia. Interestingly, isolates with a sialylated LOS locus class were significantly more 
often from patients with a Charlson index score ?1. This finding further puts into question the 
role of sialylated LOS in C. jejuni bacteremia of patients without significant underlying 
diseases. 
 
In conclusion, it is strongly emphasized that in order to understand the real significance of 
certain bacterial characteristics for the outcome of Campylobacter infection, experimental in 
vitro models must be complemented with studies on clinical, non-selected, series. 
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7. Conclusions 
 
1. Ciprofloxacin  resistance  was  not  associated  with  a  more  severe  course  of  
Campylobacter infection; rather, isolates highly susceptible to ciprofloxacin 
seemed to cause more severe infection, characterized by bloody stools and need for 
hospitalization (I). Further, the majority of Campylobacter bacteremia isolates were 
susceptible to all antimicrobial agents tested, including ciprofloxacin (III). 
 
2. None of the putative virulence factor genes ceuE, cgtB, ciaB, cj0486, pldA, virB11, 
or wlaN, nor the operon cdtABC, nor production of GGT, were significantly,  or 
independently associated with more severe symptoms among the C. jejuni enteritis 
patients. However, multivariate analyses revealed that ceuE and cj0486 were 
significantly associated with C. jejuni isolates of foreign origin, and production of 
GGT was associated with isolates of domestic origin (II). The C. jejuni bacteremia 
isolates essentially showed a similar proportion as being positive for the genes 
ceuE, ciaB, virB11,  as  well  as  the  expression  of  GGT,  but  the  fucose  permease  
gene cj0486 was comparatively less prevalent among the bacteremia-associated 
isolates than among the enteritis-associated ones. 
 
3. The patients with C. jejuni or C. coli bacteremia were moderately young, and the 
majority had no significant underlying diseases. Appropriate antimicrobial 
treatment did not seem to affect  the outcome of C. jejuni or C. coli bacteremia to 
any greater extent, neither with regard to <30 d mortality, nor when the duration of 
hospitalization was compared to that of those who received inappropriate, delayed 
appropriate, or no antimicrobial therapy (III). 
 
4. Among the C. jejuni bacteremia isolates a striking over-representation of isolates of 
the otherwise quite uncommon ST-677 CC occurred. Although serum resistance 
was not needed for C. jejuni to cause a bacteremic infection, the isolates of the ST-
677 CC were actually significantly more serum resistant than others. Only 23% of 
blood culture isolates had sialylated LOS, but sialylated LOS, and particularly LOS 
locus class C, was associated with patients’ having significant underlying diseases. 
These results indicate that certain genotypes of C. jejuni may lead to bacteremia 
more easily than others (IV). 
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